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Although renal transplant is the preferred modality for end-stage renal disease, it 
brings with it a number of challenges primarily associated with lack of individualized 
approach. The goals of the present project were: (1) to determine the most significant 
and clinically practical predictors of kidney transplant outcomes (patient survival, 
allograft survival, posttransplant complications) using United States Renal Data System 
(USRDS) data; (2) based on the selected predictors, to generate prediction models of 
renal transplant outcomes. 
Our initial study developed prediction models using logistic regression and tree-
based algorithms derived from data provided by the United Network of Organ Sharing 
(UNOS). A series of follow-up projects, using data supplied by the United States Renal 
Data System (USRDS), was performed.  We were able to capture significant 
associations between donor, recipient, and transplant procedure variables (that could 
not be derived from UNOS data) and the allograph and recipient survival. Among our 
important findings, compared to peritoneal dialysis (PD), hemodialysis is associated with 
increased risk of graft failure and recipient death; preemptive retransplantation is 
associated with an increased risk of graft failure; increased time on dialysis between 
transplants is associated with a negative effect upon graft and recipient survival in most 
patient subgroups; short-term (6 months or less) dialysis had no negative effect on graft 
survival compared to preemptive transplants; certain socioeconomic factors, such as 
higher education level, citizenship, and type of insurance coverage, influenced graft and 
recipient outcomes, independent of racial differences; and that one particular 
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immunosuppressive medication regimen was superior to others in prolonging graft and 
recipient survival. 
Based on these results, we developed a more comprehensive prediction model 
of the graft outcome using URSDS data using logistic regression and tree-based 
models.  The new models included both deceased and living donor graft recipients, was 
based on the longer list of pertinent predictors while still being practical in the clinical 
setting, and addressed the probability of graft failure at five different time points (1, 3, 5, 
7, and 10- year allograft survival).  The models have been validated on the independent 
dataset and demonstrated performance suggesting implementation in the clinical 
decision support system.     
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1.1. Statement of the problem 
 
Renal transplant recipients represent a large subgroup of patients with chronic 
kidney disease (CKD).  Renal transplant is a preferred modality of treatment for end-
stage renal disease (ESRD), as it is associated with lower comorbidity, better recipient 
survival [1-3], improved quality of life [4], and lower medical expenses [5] than those of 
patients remaining on the transplant waiting list [6, 7].  However, since organ 
transplantation requires surgical intervention, aggressive immunosuppression, frequent 
blood sampling, patient monitoring, and other diagnostic studies, it is associated with 
serious complications mostly attributed to therapy [8, 9].  In particular, 
immunosuppressive therapy, a core method required of successful transplantation, has 
a narrow therapeutic window.  Insufficient immunosuppression might predispose 
recipients to acute organ rejection and shortened allograft survival, while overaggressive 
immunosuppression might cause complications due to toxicity (e.g, cancers, diabetes 
mellitus [DM], hypercholesterolemia, osteoporosis) [10-13] or life-threatening 
opportunistic infections (e.g., bacterial infections, Epstein-Barr virus [EBV], 
cytomegalovirus [CMV], and polyoma BK virus) [14-16].   
If the probability of specific outcomes (e.g., allograft failure, infection, cancers, 
diabetes) could be estimated by reliable risk-stratification tools, the patient-specific 
estimates would be very useful for individualizing therapeutic approaches. While 
individual factors associated with allograft survival and posttransplant complications 
(acute rejections, infections, cancers, diabetes) are to some extent known, in complex, 
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real-life situations where several factors are at play, it is difficult to estimate the risks of 
particular outcomes.   
Developing risk stratification tools (i.e., a scoring systems and a decision support 
system [DSS]) based on predicted long-term outcomes of transplantation for individual 
patients might accomplish several important goals: (1) indicating donor-recipient 
combinations that predict favorable or poor outcomes; (2) identifying adjustment of 
modifiable factors that are highly predictive of allograft survival; and (3) identifying 
immunosuppressive strategies that predict improved allograft survival and limited 
complications in specific patients.  Predicting important clinical events with subsequent 
risk-stratification of long-term posttransplant outcomes would represent a very important 
step towards individualized patient therapy, as opposed to protocol-driven approaches, 
where the individual factors of the recipient, donor, and transplant procedure are not 
considered in combination.  However, the actual prediction of the outcome is impossible 
without using mathematical tools due to complexity of the associations and their 
interactions.   
Using informatics tools it is possible to develop the prediction model of long-term 
kidney allograft survival, that can be used in the development of a decision support 
system. 
 
1.2. The need for outcome prediction in renal transplantation 
 
1.2.1. Transplantation is a preferred method of renal-replacement  
therapy 
The number of patients with ESRD in the USA is approaching half-a-million; in 
most of the cases, the kidney function is being replaced by dialysis [17].  Mortality in 
patients on dialysis is 10 to 20 times higher than that of the general population [18, 19].  
Renal transplantation, limited by a shortage of kidney donors [20], significantly improves 
survival of the patients [17].  With the introduction of new immunosuppressive 
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medications, short-term allograft outcomes have improved considerably [21], while long-
term survival and chronic allograft nephropathy still present a problem [22].   
Increased patient survival [1-3], quality of life [4], and decreased medical 
expenses [5] occur as a result of kidney transplantation compared to patients remaining 
on the transplant waiting list (usually on chronic dialysis). At the same time, the 
transplant procedure and the posttransplant course carry their own risks (e.g., surgery 
and anesthesia, immunosuppressive medications, lipid abnormalities, hyperglycemia, 
cancers, infections) that may shorten the life span of the recipient.  
 
1.2.2. Predicting the outcome of transplantation is difficult 
Health care providers and patients face several important questions before a 
transplant such as: is transplantation always beneficial compared to dialysis?; should 
one receive a transplant now and have the benefit of shorter time on dialysis, or wait for 
the kidney with a better match?; should a patient with multiple comorbidities receive a 
kidney transplant at all, and if so, how it is going to affect his/her life expectancy?; if 
there are several living donors available, who is the optimal choice for a particular 
patient (based on body size, gender, antigen match, comorbidities, and their interaction, 
etc.)?; what is the best immunosuppressive strategy?   
Ideally, a computer-based DSS would integrate a large number of variables, 
allow modeling of specific constellations of predictors (i.e., issues associated with donor, 
recipient, and the transplant procedure) to reach a tailored prediction. This tool would be 
extremely valuable in the pre- and posttransplant setting, as it would help clinicians and 
patients alike to decide on the ESRD management strategy. Such a system could be 
used successfully if it predicted the degree of allograft survival, patient survival, and 
potential complications during the posttransplant course. The critical issue here is that 
patients and clinicians alike approach a transplant with virtually no sense of the patient-
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specific expected outcome.  Historically, the decision has been “transplant, yes or no?” 
The reality of posttransplant is much more of a gray area than this simple question 
suggests. 
Several modifiable factors were found to be broadly associated with transplant 
outcome. These include body size match, type of recipient immunosuppressive therapy, 
the timing of the transplant in relation to the ESRD course, HLA antigen match, etc. [23-
34]. Some of these factors have established optimal criteria (e.g., a living kidney is better 
than deceased, a preemptive transplant is advantageous compared to postdialysis 
transplant, a shorter organ cold-ischemia time is preferable, and close antigen matches 
are considered beneficial). However, clinically relevant, patient-specific treatment 
questions are difficult to answer based on these predictors in isolation. Since the number 
of variables is large, and their interactions are complex, it would be unrealistic to expect 
clinicians to reach an optimized decision unaided. To demonstrate the complexity of 
determining an optimal strategy, consider the following example: a potential recipient 
who is nearing ESRD is offered a well-matched deceased kidney available immediately. 
Should the patient accept the deceased organ to avoid dialysis or go on dialysis for an 
indefinite period in the hopes of receiving a living organ, missing the opportunity for a 
preemptive transplant? The complex nature of interactions between predictors of the 
kidney transplant outcome, as well as their intricate relationship to the outcome itself, 
makes manual prediction of allograft outcome daunting.  
 
1.2.3. Individualized prediction would improve patient management 
 
The personalized medicine paradigm proposes the diagnostic and therapeutic 
approaches to be tailored to the specific patient as opposed to “one-size-fits-all” 
approach [35, 36].  Usually considered in association with genomic information, 
personalized medicine also requires consideration of environmental factors of the 
  5 
 
recipient and donor that, when considered in combination, may help in individualizing 
therapeutic approaches. Currently in organ transplantation, use of immunosuppressive 
medications is mostly based on general clinical protocols, rather than on individual 
differences between the patients.  At the same time, the therapeutic window for most of 
the immunosuppressive medications is very narrow, where under-use may cause 
rejection, while overaggressive dosing schedule may cause long-term and life-
threatening complications (e.g., posttransplant infections, cancers, diabetes, and 
osteoporosis) [10, 13, 15].  Individual patients respond differently to immunosuppression 
and the level of the drug is not always a good predictor of the response [37].  In addition 
to drug levels, other factors pertinent to the recipient, donor, and transplant procedure 
clearly affect the response to therapy and the rate of complications [23, 38-40].   
While posttransplant management of the patients in most transplant centers is 
protocol-driven, predicting the duration of allograft and recipient survival and risk 
stratification for different outcomes (including posttransplant complications) might 
dramatically modify patient care.  Knowing the quantified risks of allograft failure, patient 
death, acute rejection, cancers, infections, and other posttransplant complications for an 
individual patient may significantly affect several decision processes, including the 
following: whether to transplant, who is the best donor, what is the preferable 
immunosuppressive regimen.  Prediction models were proposed in other areas of 
medicine, such as liver transplantation [41, 42], cancer [43-45], and cardiovascular 
disease [46-48].  NIH awarded a grant (1R01HL087115-01A1 Clinical Risk Factors for 
Primary Graft Dysfunction) to study clinical factors affecting posttransplant lung graft 
dysfunction and to develop a prediction model based on these factors.  Interestingly, 
there is another R01 grant awarded by NIH (2R01DK034238-21A1 Models for Optimal 
Liver Transplant Outcomes) to predict renal function in liver transplant recipients. At the 
same time, in the area of kidney transplantation, aside from a few reports [49-52] 
  6 
 
including those by our group [40, 53], the development and use of outcome prediction 
models are largely lacking.   
 
1.3. Prediction models in liver transplantation 
 
A Child-Turcotte-Pugh scoring system has been used in the past and has been 
recently modified to predict mortality in patients with advanced liver failure [54]. Other 
prediction models have been proposed to predict recurrent hepatitis C [55] and liver 
fibrosis [56] in liver transplant recipients.  An artificial neural network (ANN) has been 
used to predict the allograft failure in patients with liver transplantation [57]. Finally, in 
liver transplantation, a model for end-stage liver disease (MELD) based on outcomes of 
transjugular intrahepatic portosystemic shunt (TIPS) is used for prediction of liver failure 
[58] and to determine priorities in organ allocation, [41].  However, while factors 
associated with survival after liver transplantation have been evaluated [59], attempts to 
use MELD to predict the outcome of liver transplant recipients (recipient and allograft 
survival at 1 year) were unsuccessful [60].  This illustrates the need to utilize a large data 
set of data that is directly related to the outcome of interest, as opposed to the use of 
proxies (e.g., data from TIPS outcomes used to predict transplant outcomes). 
 
1.4. Prior efforts to predict kidney transplant outcome 
 
Outcome prediction is becoming increasingly important in medicine, but when a 
resource is scarce, the need for accurate prediction becomes even more evident. There 
is extensive literature dedicated to identifying predictors and risk factors of kidney 
transplant outcomes in adults [23, 61] and children [62], including the work published by 
our group [23, 63-71]. 
In addition to conventional environmental factors associated with renal transplant 
outcome, new biomarkers are currently being proposed.  To name a few, ELISpot assay 
for interferon-gamma is associated with renal function in recipients at 6 and 12 months 
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posttransplant [72].  IL-12 and IL-10 elevated pretransplant are associated with acute 
rejection [73].  Gene expression studies were also performed and showed association of 
some transcripts with acute rejection [74] and early [75] allograft function.  Renal artery 
resistance index measured by Doppler has been associated with allograft survival [76].  
However, actual prediction studies in this area are limited. In his New England Journal of 
Medicine editorial “Predicting outcomes after renal transplantation--new tools and old 
tools,” Marsden [77] describes specific markers of the renal transplant outcome. 
However, to our knowledge, there is no comprehensive model taking advantage and 
benefiting from several predictors taken together.  
Several published reports focus on the prediction of the drug kinetics or 
differential diagnoses. Prediction analysis and, specifically, an ANN were used in 
transplant patients to predict both pharmacokinetic parameters of cyclosporine [78, 79], 
tacrolimus [80], and mycophenolate mofetil [81].  An ANN was also used to differentiate 
between acute rejection and acute tubular necrosis based on the results of renogram 
and clinical parameters [82], and to assist in pathological diagnosis of acute rejection 
[83]. In addition, decision analysis models were used to assist decision making for 
specific clinical questions (e.g., treatment of ESRD in insulin-dependent diabetics) [84-
86].  
Literature dedicated specifically to the general prediction of the clinical outcomes 
in kidney transplantation is scarce.  In an early effort, Opelz et al. concluded that time-
dependent renal function and clinical grades can be used in prediction of late allograft 
failure [87].  ANNs have been used to identify patients who risk the development of 
posttransplant cytomegalovirus disease [88].  Brier et al. used an ANN to predict the 
occurrence of delayed allograft function in kidney transplant recipients [51]. They found 
that ANNs were more sensitive, but less specific, than logistic regression in predicting 
delayed graft function.  Delayed graft function is a short-term outcome, where the event 
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is reached in a few days after transplant.  This makes prediction less challenging than 
the task of predicting long-term outcome since there are very few censored data points 
and a limited chance for unaccounted factors to adversely affect the model.  Shoskes 
used an ANN to predict short-term renal transplant outcome and reported results in a 
non-peer-reviewed journal [49].  In the early work by Hennige [50], the authors used a 
multivariate model and data from 924 patients to predict 1-year survival.   
Several scoring systems predicting short-term outcomes have been proposed:  
 Scoring systems for deceased donor kidneys (deceased donor score) predicting 
short and long-term outcome were studied.[89-91].  In a recent paper based on 
217 transplantations, three prediction scores were evaluated in their performance 
of predicting short-term allograft outcome.  They demonstrated moderate 
predictive ability [92]. 
 De Bruijne et al. used Cox modeling with time-dependent renal function 
covariates for prediction of late allograft failure [52]. The project was based on a 
relatively small sample size (n=692) and a short list of predictors. Another clinical 
tool predicting mortality after kidney transplantation based on the Cox model [93] 
has been proposed based on 6,324 Canadian renal transplant recipients.  In our 
proposed project, we will have access to almost 200,000 records of renal 
transplant recipients in the USA with hundreds of variables, which provides an 
excellent opportunity to develop a comprehensive and robust prediction model 
and risk-stratification tools for several important renal transplant outcomes. 
1.5. Published reports by the author 
 
The results discussed here were previously reported in peer-reviewed 
publications.  In particular, the preliminary model discussed in Chapter 3 has been 
presented in publication [23] and is also protected by US patent [94].  Studies discussed 
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in Chapter 4 were reported as follows: The role of the renal replacement therapy 
modality discussed in Section 4.3. was published in [66].  In a follow-up project, we 
reported the role of previous renal transplantation [65] (presented here in Section 4.4), 
while the role of ESRD duration prior to transplantation was presented in [64] and 
discussed below in Section 4.5.  In more recent papers, we discussed the role of 
recipient socioeconomic status [95] (presented here in Section 4.6.) and the role of 
immunosuppressive medications [96] (presented in Section 4.7).  Finally, we reported 
the results of tree-based modeling presented in Chapter 5 [97]. 
 
1.6. Specific aspects of medical informatics applicable to 
this project 
 
1.6.1. Manipulating a large dataset 
 
In this project, the data were obtained from several separate USDRS files that 
had to be linked to each other.  Some of the medical data format had to be changed.  
We performed data cleaning and validation.  Finally, we performed imputation 
procedures to prepare the dataset for analysis. 
 
1.6.2. Knowledge discovery in the databases 
 
We used specific KDD techniques, including recursive partitioning, artificial 
neural networks, as well as more traditional logistic regression to establish the feasibility 
of the prediction modeling and by comparing different models to select the optimal 
statistical approach.   
 
1.6.3. Variable selection for the prediction modeling 
 
Variable selection for the prediction modeling is an integral part of machine 
learning, and was performed prior to the construction of the prediction models. 
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1.6.4. Creation and validation of the prediction model: The core  
of the decision support system 
 
In this project, we generated several mathematical models predicting the 
probability of the kidney allograft failure at different time points of the posttransplant 
period.  Prediction models represent either a regression model or a recursive partitioning 









Clinically useful individualized estimates of long-term kidney transplant outcomes  
can be generated by using mathematical models to combine standardized data collected 
on recipient characteristics, donor characteristics, and transplant procedures. 
 
2.2. Project aims 
 
The specific goals of the present project are the following: 
1) To determine the most significant and clinically practical predictors of 
kidney transplant outcomes (patient survival, allograft survival, posttransplant 
complications) using United States Renal Data System (USRDS) data. 
2) Based on the selected predictors, to generate prediction models of renal 
transplant outcomes. 
 
2.3. Impact on patient care 
 
While realizing the potential caveats concerning observational and retrospective 
studies, employing prediction models and developing risk-stratification tools may be 
used successfully in clinical practice to accomplish the following:  
(1) manipulate modifiable factors (e.g., donor selection, diet, behavior, 
medications) in pretransplant and posttransplant periods to potentially prolong allograft 
and patient survival;  
(2) create evidence-based recipient and donor counseling regarding pre- and 
posttransplant strategies and range of likely outcomes;  
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(3) individualize selection of immunosuppressive regimens in order to 
minimize the risk of allograft rejection and posttransplant complications, and thus to 
expand overall allograft and patient survival;. 
(4) extend the predictive models to predict long-term outcome in the general 
population of patients with CKD. (Here, the infrastructure designed to collect and 
analyze the data used in this project will also be configured to accommodate new data 
types). 
(5) to advance future research through utilizing the hypotheses generated in 
this study and by using research resources (including data collection and DNA storage) 
developed at the end of this project;  
(6) generate hypotheses and provide important targets for future 
interventional studies by identifying important predictors of patient outcome; 
(7) and finally, employing the proposed study to address the Healthy People 
2010 statement to improve kidney transplant outcomes, and thereby accomplishing the 
goal of reducing  the consequences of CKD.  
  
 
3. PRELIMINARY MODEL: 3-YEAR ALLOGRAFT SURVIVAL 
 
 
3.1. Introduction and project goal 
 
Attempts have been made to develop prediction models of graft survival (mostly 
short-term) [98] based on data available using different statistical models such as Cox 
regression [50] and artificial neural networks [49].  The goal of this initial study was to 
evaluate the set of United Network of Organ Sharing (UNOS) records (1990-1998) to 
identify pretransplant factors affecting 3-year allograft survival in order to generate a 
prediction model that would accurately identify patients at risk for 3-year allograft failure 
using logistic regression and a tree-based algorithm. To assure practical use of the 
prediction model in pretransplant evaluation and recipient counseling, only variables 






Between the years 1990 and 1998, from the U.S. Scientific Registry of 
Transplant Recipients (supplied by UNOS), we selected patients with ESRD who had 
undergone kidney or kidney-pancreas transplantation. The dataset includes transplants 
done in infants and young children as well as old age (minimal age below 1 year, and 
maximum age 98 years).  To protect patient privacy, follow-up dates and transplant 
dates were shifted randomly by 1 to 180 days.  Dates were shifted by the same amount 
for any given record so that the difference between the dates is preserved.  Independent 
variables available for analysis included age, gender, race, height and weight for both 
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donor and recipient, recipient cause of end-stage kidney disease, type of pretransplant 
renal replacement therapy, number of previous kidney transplants and pretransplant 
blood transfusions, recipient most recent creatinine and donor terminal creatinine, 
history and duration of diabetes in hypertension in the donor, number of HLA match and 
mismatch, cold ischemia time, kidney or kidney and pancreas transplant, and transplant 
center code.  The outcome variable was 3-year graft survival, and the end point was 
defined as allograft failure.  Patient death with functioning graft was not included in the 
definition of graft failure.  Information regarding most of the variables used in our 
analysis was collected by UNOS beginning October 1, 1987.  However, several 
variables (donor history and duration of diabetes and hypertension, recipient most recent 
serum creatinine and donor terminal creatinine) were collected by UNOS only since 
4/1/1994.  Furthermore, donors’ most recent creatinine levels were collected only for 
nondialyzed patients between 4/1/94 and 10/25/99 with collections from all patients 
beginning only after 10/25/99 [23].   
 
3.2.2. Data cleaning and imputation 
 
The initial dataset consisted of 102,686 records.  Independent variables initially 
planned to be included in the analysis, but missing a large number of entries, were either 
eliminated (recipient creatinine levels were missing in 89.2% of the entries) or 
categorized (previous number of kidney transplants, donor terminal creatinine levels, 
donor duration of diabetes, and donor duration of hypertension were missing in 87.3%, 
60.6%, 63.7%, and 60.7% of the entries, respectively, and were converted into 
categorical variables with a separate code for missing values).  The following variables 
were considered erroneous and were replaced with blank values: cold ischemia time =0 
(n=376), cadaveric donor creatinine >3 mg/dl or 26.5 mmol/dl (n=923), donor or recipient 
height <45 cm or >210 cm (n=211, n=6), donor or recipient weight <1 kg or >340 kg 
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(n=21, n=29).  A number of records with critical information being incomplete or deemed 
to be unreliable or erroneous had to be eliminated.  Records missing both height and 
weight (for either donor or recipient) were eliminated.  In the remaining missing records, 
donor and recipient height and weight were imputed using a tree-based model with 
height (for weight imputation), weight (for height imputation), age, gender, and race as  
independent variables.  The imputation algorithm for recipient height (missing 90% of the 
values) was tested using 8,282 USRDS patients with complete data for age, weight, 
height, gender, and race from DMMS Waves 3 and 4 studies.  The dataset consists of a 
random sample of all ESRD patients on January 1, 1994.  As a test of reliability, the 
intra-class correlation coefficient was calculated using SPSS (SPSS Inc., Chicago, IL).  
Based on the Landis and Koch guideline for evaluation of the reliability coefficient [99], 
our correlation coefficient of 0.76 for the predicted height values has substantial 
agreement with the actual observed heights.  Records with missing and indeterminate 3-
year outcome were deleted; therefore, the dataset was biased towards a higher 
proportion of failed grafts.  As a result, values of the percent survival have only relative 
meaning and are used for the purpose of comparison between groups studied.  Two of 
the categorical variables had more than 34 levels (transplant center code, cause of 
ESRD).  Based on the possibility that transplant center volume may have an effect on 
the outcome, a five category variable was created: transplant centers codes were 
grouped into quintiles according to total number of transplants done between ’90 and ’98 
(1= 1-83; 2= 84-209; 3= 210-355; 4= 356-615; 5= 616-2529).  Causes of ESRD were 
grouped into deciles by total number of transplants with known 3-year survival.  The final 
dataset consisted of 37,407 records. 
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3.2.3. Statistical analysis 
 
Bivariate analysis was performed using cross-tabulation and comparison of graft 
survival in the subgroup using the Chi-square test. The Friedman supersmoothing 
method was used to fit the curve in bivariate analysis.  Discrimination was determined by 
area under receiver operating characteristic (ROC) curve and Chi-square for logistic 
regression models.  Model calibration was assessed using the Hosmer-Lemeshow 
goodness-of-fit test.  For the purpose of prediction analysis, all records were randomly 
assigned either to a “training” set (n=25,000), used for knowledge acquisition and model 
development, or to a “testing” set (n=12,407), used to validate the models.  Predicted 
probabilities of 3-year graft survival were generated on a testing set and were compared 
with the actual patient outcomes.  The predicted probability of the graft survival with 
group-average observed graft survival was used to compare the performance of the 
models.  Also, 2x2 contingency tables were used to determine positive and negative 
predictive values.   
Multivariate statistical models used in the analysis included logistic regression 
and classification trees.  In certain situations, traditional statistical methods are poorly 
suited for complex interactions or detecting patterns in the data.  Many possible predictor 
variables may violate the normality assumptions necessary for parametric analysis.  In 
addition, the results of traditional methods sometimes may be difficult to use.  Therefore, 
along with a traditional regression model that assumes linear relationship between 
predictors and the outcome, we decided to use a less commonly used tree-base model, 
which does not require the linearity assumption, and was used in clinical prediction 
before [100].  Tree-based modeling is an exploratory technique for uncovering structure 
in data which generates a collection of many rules displayed in the form of a binary tree 
[101].   We used the S-Plus statistical software package (MathSoft, Inc., Seattle, 
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Washington) for bivariate analysis and tree-based modeling and SAS (SAS Institute, 




3.3.1. Comparison between initial and final datasets 
 
The elimination of the large number of records could potentially bias the dataset; 
therefore, after completing the data cleaning described in the previous section, we 
compared the final dataset (n=37,407) to the initial one (n=102,686).  The final dataset 
had the same donor and recipient mean age, height, weight, number of matched and 
mismatched antigens, and cold ischemia time as the initial dataset, as well as the same 
distribution of donors and recipients by gender, dialysis type, race, presence of DM and 
HTN in donors’ number of pretransplant transfusions, and transplant procedure (data not 
shown).  Compared to the initial dataset number, the number of transplant centers in the 
final datasets has not changed.  Therefore, we concluded that even after the elimination 
of a large number of records, the final dataset is still representative of the initial sample.  
 
3.3.2. Bivariate analysis 
 
3.3.2.1. Donor and recipient characteristics 
 
Young as well as elderly donors and recipients have lower 3-year graft survival 
(p<0.001).  There were differences in outcome associated with donor and recipient 
gender and race.  Kidneys from the donors with both DM and HTN had the worst 3-year 
survival (59.3%), while those from the donors without either had the best outcome 
(76.3%).  Kidneys from either diabetic or hypertensive donors were roughly in the middle 
(66.2% and 64.3%, respectively) (p<0.001).  Increased duration of HTN and/or diabetes 
(from 1 to 5 years by 1 year increments) in the donor was associated with worse 
outcome (p<0.001 for both).  There is no relationship between donor terminal creatinine 
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and graft survival.  There were differences in outcome associated with different 
etiologies of renal failure (data not shown).  Patients with no dialysis history (preemptive 
transplant) had the best 3-year graft survival (81.3%, n=1,940) followed by those with 
history of peritoneal dialysis (76.1%, n=4,591) and then hemodialysis (73.0%, n=11,542) 
(p<0.001).  A previous transplant history worsened 3-year survival in almost a linear 
fashion with 76.7% survival in recipients with no previous transplant history: 70.9%, 
62.1%, and 56.9% in those with one, two and more than two previous transplants, 
respectively (p<0.001).  The number of pretransplant transfusions did not significantly 
affect graft survival in bivariate analysis.   
 
3.3.2.2. Transplant procedure: Matching donor and recipient 
Three--year survival improves and declines in a linear fashion with increasing 
numbers of matched and mismatched antigens, respectively (p<0.001).  Donor/recipient 
BMI vs. 3-year graft survival looks almost like a bell-shaped curve with the best outcome 
associated with the donor/recipient BMI equal to 1.  The worst survival was in grafts from 
relatively small donors to large recipients (p<0.001). Transplant centers with a low 
volume of transplants had variable outcomes, while in those with a high number of 
transplants, the outcome was relatively uniform.  There was a slight downward trend in 
the relation of 3-year graft survival to cold ischemia time.  Recipients of kidney-pancreas 
transplants had better 3-year kidney survivals (82.5%, n=3,243) than those receiving a 
single (i.e., kidney) transplant (75.7%, n=33,526) or en-bloc kidneys (68.2%, n=638) 
(p<0.001).   
 
3.3.3. Mulitvariate analysis 
 
The entire dataset (n=37,407) was initially included in a logistic regression model 
predicting 3-year graft survival.  Using stepwise forward selection, we set a significance 
level of 0.05 for independent variables to enter the model.  The variables and model 
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information are presented in Table 1.  Odds ratios with 95% confidence intervals for the 
binary variables identified by the model are presented graphically (Figure 1).  Deciles 6 
and 7 of ESRD causes were identified as having a significantly higher risk of allograft 
failure, and the odds ratios of 3-year graft survival were 0.75 (95% CI 0.6-0.9) and 0.78 
(95% CI 0.7-0.9), respectively [23].   
Causes of ESRD in these categories that demonstrated less than 70% 3-year 
survival are membranous nephropathy (66.2%), cyclosporin nephrotoxicity (68.3%), 
analgesic nephropathy (68.8%), type II insulin dependent diabetes mellitus (65.6%), 
Henoch-Schönlein purpura (69.7%), mesangio-capillary type 1 glomerulonephritis 
(68.5%), and hemolytic uremic syndrome (54.8%). 
Model discrimination using the c index (area under the receiver operating 
characteristic curve) was 0.653.  This is the probability that for a randomly chosen pair of 
patients, the predicted and observed graft survivals are concordant.  Model calibration 
was assessed using the Hosmer-Lemeshow goodness-of-fit test.  Since the p-value, 
p=0.63, of this test was not significant, the model’s estimated probabilities of 3-year graft 
survival are not significantly different from the actual survival of patients over groups 
spanning the entire range of probabilities. 
3.3.4. Prediction analysis 
 
To generate the prediction model, we randomly selected 25,000 records as the 
training set, while the remaining 12,407 records were designated as a testing set and 
were used to compare predicted and observed 3-year allograft survival.  A logistic 
regression model was again generated on the training set only.  This model was 65% 
concordant and 34.5% discordant, while the c index was 0.653.  Using the variables and 
parameter estimates generated with the training set, we calculated the probability of 3-
year graft survival in the testing set.  All records were divided into 10 groups based on  
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Table 1.  Predictors of the outcome (3-year graft survival) identified by logistic 
regression for the whole dataset (n=37,407) 
 
Independent variable 















      
Intercept 1.332 89.474 <.0001   
Donor age -0.0145 297.87 <.0001   
Donor BMI 0.0015 9.0748 0.0026   
Recipient BMI -0.0121 42.774 <.0001   
Recipient age 0.0146 231.46 <.0001   
HLA match 0.1336 206.65 <.0001   
Cold ischemia time -0.0079 35.701 <.0001   
Recipient is male 0.0648 6.4246 0.0113 1.067 1.015-1.122 
Donor is male 0.1467 30.611 <.0001 1.158 1.099-1.22 
Terminal donor creatinine 0.1-0.5 -0.2087 10.343 0.0013 0.812 0.715-0.922 
Terminal donor creatinine >1.5-2 -0.2389 12.579 0.0004 0.787 0.69-0.899 
Terminal donor creatinine >2-2.5 -0.4012 8.8319 0.003 0.67 0.514-0.872 
Previous number of transplants =1 -0.4078 11.241 0.0008 0.665 0.524-0.844 
Previous number of transplants =2 -0.8534 35.723 <.0001 0.426 0.322-0.564 
Previous number of transplants >2 -1.1078 25.17 <.0001 0.33 0.214-0.509 
Previous number of transplants 
unknown -0.0454 0.1503 0.6982 0.956 0.76-1.202 
Donor is Black -0.3229 66.57 <.0001 0.724 0.67-0.782 
Donor is Hispanic -0.1247 7.1664 0.0074 0.883 0.806-0.967 
Recipient is Black -0.4726 263.48 <.0001 0.623 0.589-0.66 
Recipient is Asian 0.2201 8.065 0.0045 1.246 1.071-1.451 
Recipient was never dialyzed 0.2001 9.7585 0.0018 1.222 1.077-1.385 
Recipient dialysis modality is unknown 0.1754 33.774 <.0001 1.192 1.123-1.264 
Donor: HTN (but not DM) -0.3701 32.775 <.0001 0.691 0.608-0.784 
Donor: no diabetes -0.571 13.845 0.0002 0.565 0.418-0.763 
Donor: duration of DM >= 5 years -0.5702 14.815 0.0001 0.565 0.423-0.756 
Donor: duration of HTN >= 5 years 0.1856 4.7968 0.0285 1.204 1.02-1.421 
Simultaneous kidney-pancreas 
transplant 0.3052 30.044 <.0001 1.357 1.217-1.513 
Transplant procedure: en-block 
transplant -0.6445 47.954 <.0001 0.525 0.437-0.63 
Transplant procedure: double kidney -12.727 0.021 0.8849 <0.001 >999.99 
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Table 1. Continued  
 
Independent variable 















Transplant procedure: whole pancreas 
/ right kidney -1.413 3.9032 0.0482 0.243 0.06-0.989 
Transplant center volume (>83-209) -0.1436 8.2045 0.0042 0.866 0.785-0.956 
Transplant center volume (>355-615) -0.1115 14.812 0.0001 0.895 0.845-0.947 
Number of transplants for this 
diagnosis >46-77 (6th decile) -0.2942 7.2995 0.0069 0.745 0.602-0.922 
Number of transplants for this 
diagnosis >77-196 (7th decile) -0.2435 7.9364 0.0048 0.784 0.662-0.929 


































Figure 1.  Odds ratios of the 3-year graft survival based on the logistic regression model 
 
 
deciles of predicted probability of graft survival (0-10%, >10-20%, >20-30%, etc.).  The 
observed percentage of 3-year graft survival was calculated for each group, and the 
observed graft survival was compared to the expected survival.  Since there was only 
one patient in the >10-20% group, that group was combined with the >20-30% group to 
produce a >10-30% group.  The midpoint of each group’s probability range was used as 
the expected percent survival.  As shown in Figure 2, the prediction of the probability of  




























Figure 2.  Results of the prediction of 3-year graft survival using a logistic regression 
model on the testing dataset.  All patients were divided in ten groups based on predicted 
probability of graft survival.  The observed group averaged graft survival is compared to 
the predicted probability. 
 
graft survival  from the training model achieved a very good match with the observed 
survival of the testing set, with a Chi-square value of 6.15 and p=0.63, which shows no 
significant difference between observed and predicted category, and a correlation of 
r=0.998. 
We converted predicted allograft failure probability into a binary variable (graft 
survival = “yes” or “no”) using a cut-point of 50% probability.  The results were compared 
by means of a 2x2 contingency table.  The positive predictive value of allograft survival 
with the model was 76.0%, and the negative predictive value was 63%. 
Probability of 3-year graft survival 
observed vs. predicted by logistic regression 




























  24 
 
3.3.4.1. Tree-based model 
We used a tree-based model to identify predictors of 3-year graft survival and to 
develop a prediction model.  The outcome of a cross-validation procedure in the form of 
deviance plotted against number of terminal nodes (tree size) was analyzed, and the 
optimal size of the tree was determined to be equal to 54 terminal nodes.  To identify 
predictors of the outcome, the initial tree was constructed on the entire dataset and 
pruned to 54 terminal nodes.  The following 17 predictors of outcome (in order from the 
root of the tree to the terminal nodes) were identified by the tree-based model: recipient 
race, donor age, recipient weight, cold ischemia time, recipient height, previous number 
of transplants, recipient age, number of matched HLA antigens, donor race, cause of 
end-stage renal disease, recipient gender, number of mismatched HLA antigens, 
recipient BMI, recipient weight, presence of diabetes and/or hypertension, donor height, 
and donor/recipient BMI.  The residual mean deviance of the model was 1.03 and the 
misclassification error rate was 0.23. 
The new tree-based model was built upon a training set and validated on the 
testing set.  Using the model generated with the training set, we calculated the 
probability of 3-year graft survival in the testing set.  All records were divided into 10 
groups based on deciles of predicted probability of graft survival (0-10%, >10-20%, >20-
30%, etc.).  The observed percentage of 3-year graft survival was calculated for each 
group.  The observed graft survival was compared to the expected survival.  Since there 
were only six patients in the 0-10% and >10-20% groups taken together, those groups 
were combined with the >20-30% group to produce a 0-30% group.  For the same 
reason groups >30-40% and >40-50% were combined to produce a >30-50% group.  
The midpoint of each group’s probability range was used as the observed percent 
survival (Figure 3).  The prediction of the probability of graft survival from the training 
model achieved a good correlation with the observed survival of the testing set  
















Figure 3.  Results of the prediction of 3-year graft survival using a tree-based model on 
the testing dataset.  All patients are divided into seven groups based on predicted 
probability of graft survival.  The observed group-averaged graft survival is compared to 
the predicted probability. 
 
(r=0.984).  We converted predicted allograft failure probability into a binary variable (graft 
survival = “yes” or “no”) using a cut-point of 50% probability (Figure 4).  The graph 
represents the model in a form of a dichotomized tree, where each node presents a 
question regarding the value of a single independent variable.  If the answer to the 
question is “yes,” users move to the next node by way of the left branch (or right branch, 
if the answer is “no”) until it reaches the terminal node, which predicts 3-year graft 
survival (Y or N).  The results were compared by means of a 2x2 contingency table.  The 
positive predictive value of the allograft survival with the model was 76.0% and the 
negative predictive value was 53.8%. 


































Figure 4.  Tree-based model built on the training dataset.  D- donor, R – recipient, Tx – 
transplant, CIT – cold ischemia time, “Y” and “N” at the terminal nodes of the tree 
correspond to predicted 3-year graft survival (yes or no).   
Transplant procedure group 1: left /right, or en-bloc kidney with or without the whole     
pancreas with duodenum or whole pancreas with duodenal patch / left kidney 
Transplant procedure group 2: double kidneys, pancreas segment with left kidney, whole 
pancreas with duodenum and double kidneys, whole pancreas with right kidney 
Transplant procedure group 3: pancreas segment and left kidney, whole pancreas with 
duodenum and right or en-bloc kidney, whole pancreas and left kidney 
Transplant procedure group 4: left /right / en-bloc kidney, whole pancreas with 
duodenum and left kidney, whole pancreas with duodenal patch and left kidney, whole 
pancreas and right kidney. 
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Factors affecting kidney allograft survival were evaluated previously, based on 
local datasets and national databases.  In this project, we evaluated a large national 
dataset which includes a relatively new collection of data covering all renal and kidney-
pancreas transplants between 1990 and 1998. Using strict criteria, we eliminated 
records with incomplete information and made careful imputation of some variables.   
 
3.4.1. Discussion on dealing with missing information in UNOS  
dataset 
 
While cleaning the data, we encountered certain problems with missing and 
poorly reported values.  The amount of misreported or missing information in the1990-
1998 UNOS dataset can be explained by several factors that need to be considered by 
researchers analyzing the data.  As mentioned above, certain variables may not have 
been collected over the entire time period of the cohort.  For example, donor history and 
duration of diabetes and hypertension, and recipient most recent serum creatinine and 
donor terminal creatinine were collected only since April of 1994.  Additionally, voluntary 
data submission via paper form (with some fields not mandatory) account for much of 
the missing information.  It has been speculated that this is the reason that height and 
weight are not populated well (e.g., recipient height is missing in approximately 90% of 
the values).  In some cases, the field may not be relevant in that particular instance, so 
the member may have chosen to leave it blank (e.g., data for PRA tends to be entered 
only if the patient is sensitized [PRA 80 or above]; otherwise, it is left blank).  One may 
expect improved quality of data in the future.  The number of outstanding forms has 
been steadily declining in recent years For example, there were almost 150,000 
outstanding forms in April of 2000 and 56,000 in September 2002 (UNOS, personal 
communications).  UNet, the online transplant data entry system, was implemented in 
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October 1999.  The new system of on-line data entry employed real-time data quality 
control, forcing the user to enter the data in a correct and unified format.  Therefore, the 
quality of information should substantially improve.  Thus far, the effect of the new 
system on the individual variables over time has not been studied closely.  In this study, 
missing categorical variables were coded as a new category and missing continuous 
variables were replaced using appropriate data imputation methods.  In particular, a 
tree-based algorithm was used for height and weight imputation.  The algorithm that we 
developed has been shown to have good precision when validated on a separate 
database derived from USRDS Wave 3 and 4 study patients.  Tree-based imputation 
can be a useful tool for the researchers analyzing the datasets with missing values for 
the anthropometric characteristics.  After careful imputation, the results and conclusion 
of our analysis should not be affected by various causes of missing data (UNOS not 
collecting it vs. poor reporting).  During cleaning of the initial dataset, we tried to 
preserve as much useful information as possible and at the same time eliminate 
potentially erroneous, incomplete, or unreliable information.  A significant number of 
records had to be eliminated as some critical information was missing or deemed 
unreliable.  
 
3.4.2. Individual predictors of the transplant outcome 
 
Our bivariate and multivariate analyses demonstrated the importance of several 
pretransplant donor, recipient, and procedure variables in predicting 3-year graft 
survival; in particular, we found that the number of previous kidney transplants in 
recipients has a direct relationship to the transplant failure rate, and that diabetes and  
hypertension worsen the outcome.  The relationship between donor and recipient age, 
race, gender, and 3-year graft survival previously reported [27, 34] proved to be 
nonlinear. The number of HLA matched/mismatched antigens has a very strong linear 
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relationship with the percent 3-year graft survival. On the other hand, the effect of cold 
ischemia time is much less dramatic by bivariate analysis than we initially expected and 
that was previously reported [102].  The transplant center effect was studied before [103] 
and showed only a very slight difference between the large and small centers.  In our 
study, centers with higher number of transplants have more similar outcomes, while the 
outcomes of the smaller centers exhibited considerable variability.  This may represent 
either a regression to the mean or a true phenomenon of more uniform outcome that 
comes with greater experience.  The logistic regression model selected transplant center 
volume as a predictor of the outcome, with centers having less experience increasing 
the risk of 3-year allograft failure.  Some of the causes of end-stage renal disease in a 
recipient as a predictor of the outcome were described before [104].  In addition, we 
evaluated all the diagnoses with known 3-year outcome that we could derive from UNOS 
database.  We confirmed previously reported beneficial effects of preemptive 
transplantation [105-107].  Body mass index (BMI) of donor and recipient as well as 
recipient obesity in relation to outcome has been discussed in the   literature and has 
been found to have an important role in the prediction of the kidney allograft outcome in 
some studies [108, 109], while in others obese (high BMI) transplant recipients  have 
similar outcomes to nonobese patients [110].  In our study, both donor and recipient 
BMIs were found to be good predictors of outcome by means of bivariate and 
multivariate analysis.  Since successful transplantation of adult living donor kidneys into 
infants and small children with good long-term outcome has been shown in a small study 
[111], the unexpected, almost bell-shaped curve (Figure 3) describing the relationship 
between donor-to-recipient BMI and graft survival is surprising.  This may represent 
either the deleterious effect of donor obesity [108] or the impact of poor recipient 
nutritional status.  This relationship needs to be further evaluated in prospective studies 
and may be an important factor affecting the selection of the donor.  
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3.4.3. Predictive model issues 
The novel part of this study is the predictive model.  The time period of interest 
covers the “postcyclosporine era”; however, the 1990s were associated with changes in 
immunosupression protocols and surgical techniques and therefore, the database 
represents a very heterogenous population.  This heterogeneity may potentially affect 
the performance of the prediction models, especially since we included in the analysis 
only a limited number (26) of pretransplant independent variables.  In designing the 
study, our intent was to develop a prediction model for use prior to transplantation; 
therefore, we excluded posttransplant variables that were not available until after the 
transplant procedure. We did not analyze the impact of immunosuppressive therapy, 
immediate posttransplant graft function, and episodes of acute rejection, since this 
information was not available prior to transplant.  Along with the conventional logistic 
regression model, we used a tree-based model never before used to analyze transplant 
outcome.  This model represents a relatively new approach compared to conventional 
regression analysis of the data. Interest in this statistical approach has been increasing 
over the last 10 years.  Several features make tree-based models a powerful tool for 
building a prediction algorithm that can be successfully used in practice. The tree-based 
model works when the regression variables are a mixture of categorical and continuous 
variables, and it is often able to uncover complex interactions between predictors which 
may be difficult or impossible to uncover using traditional multivariate techniques.  The 
algorithm is nonparametric, so no assumptions are made regarding the underlying 
distribution of values of the predictor variables. The tree-based model identifies 
"splitting" variables based on an exhaustive search of all possibilities, even in problems 
with many hundreds of possible predictors.  Simultaneously, it requires relatively little 
input from the analyst.  This graphical algorithm, presented as a collection of simple 
binary rules, is much simpler to interpret by a nonstatistician than the multivariate logistic 
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regression.  Thus, it can be used in the decision-making process without doing any 
additional calculations, and therefore is more likely to be followed in clinical practice.   
Prediction models using logistic regression and tree-based algorithms are 
developed in this study on the large set of data, and can potentially be used in recipient 
counseling and decision-making regarding cadaveric renal transplants. The relatively low 
area under the ROC curves of the initial models suggests that a longer list of the 
potential predictors should be evaluated.  However, the prediction algorithms generated 
on the training dataset can be successfully used in practice to identify the probability of 
3-year kidney allograft survival, since both models achieved good precision in predicting 
the probability of the graft survival on the separate set of data.  There is an experience of 
using similar data derived from univariate and multivariate analyses in a smaller study in 
a cadaveric kidney allocation decision-making study in a northern Italy transplant 
program [112].  The identification of factors that play an important role in graft survival 
helps to focus efforts of transplant programs on certain individual aspects of patient care.  
The implementation of the models that were generated in this study in the form of 
software to make it available for transplant programs and prospective transplant 
recipients may be a subject of future projects.   
 
3.5. Significant deficiencies of this project 
 
A very important deficiency of this project is a limited number of predictors.  In 
particular, none of the factors associated with the pretransplant dialysis course were 
included in the model.  Similarly, socioeconomic factors and comorbid conditions were 
left out of the model, since the information is not available in UNOS database.  
Furthermore, it is not clear in the existing literature which of the factors have a significant 
association with the outcome and therefore need to be included in the modified model.  
Furthermore, the model presented above predicted the probability of 3-year graft 
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survival, but not at any other time points.  Finally, only deceased donor transplant 
recipients were included in the reported study, while the recipients of living donor grafts 
were left out [23]. 
Based on these deficiencies, the decision was made to proceed as follows. 
1. Evaluate the association between specific variables and the transplant outcome 
in order to make a decision whether or not to include them in the final model. 
2. Build a more sophisticated model based on a more complete list of predictors 











4.1. Project goal 
 
The goal of this series of projects was to establish the association between 
previously unexplored potential predictors and transplant outcome in order to improve 
the performance of the predictive model. 
 




Using the USRDS database, we collected data on all kidney allograft recipients 
(both pediatric and adults) who underwent kidney or kidney-pancreas transplantation 
during the period of January 1, 1990 through December 31, 1999.  The follow-up data 
were collected through December 31, 2000.   
For recipients of multiple transplants, the most recent one was considered the 
target transplant (transplant of interest).  Patient records with missing information 
regarding graft or patient survival were excluded from the study.  A total of 92,844 
patients with kidney transplant were identified.  Records of patients with prior kidney 
transplants (n= 11,714) were also identified and analyzed separately.   
 
4.2.2. Study outcomes 
 
There were two outcomes in this study.  The first outcome was the time between 





the time between most recent kidney transplant and the patient’s death.  Both outcomes 
were modeled using continuous survival time variables.   
Graft failure definition did not include patient death with a functioning graft, the 
latter determined in the USRDS as a single binary variable.  In case the value of this 
variable was missing and the patient’s death date was found to be equal to the graft 
failure date, we assumed that patient died with a functioning graft, unless the cause of 
death was coded as one of the following: 3200 (graft failure: primary failure), 3201 (graft 
failure: rejection), 3202 (graft failure: technical), 3299 (graft failure: other), or 3903 
(miscellaneous: renal failure).   
Allograft outcome was censored at the earliest of the following events: loss to 
follow-up, patient death, or the study completion date (12/31/2000) and was analyzed as 
days-to-graft-failure or censor.  Patient follow-up was censored at the earliest of loss to 





The following independent variables were collected:  
1. recipient variables: recipient age, gender, race, height, weight, history of 
hypertension (HTN) and diabetes, history of prior transplant, total duration of 
ESRD, total number of transplants, mean and peak panel reactive antibody 
(PRA) levels, education level, primary source of pay, citizenship (the combination 
of the last three variables was used as a surrogate for socioeconomic status); 
2. donor variables: type of donor (cadaveric or living), heartbeating donor or not, 
donor age, gender, race, height, weight; 
3. transplant procedure variables: day of the week the transplant was done, the 
year of the transplant, number of matched HLA antigens, and cold storage time.  
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To adjust the multivariate models for recipient comorbidities, we calculated a 
comorbidity score similar to one proposed by Davis, which has been shown to be 
strongly associated with the survival in a prospective study of 97 peritoneal dialysis (PD) 
patients [113].  The comorbidity score used in this study was calculated based on the 
following coexisting conditions, each of them contributing one point to the score: 
cardiovascular disease (defined in USRDS as symptomatic cardiovascular disease or 
angina/coronary artery disease), symptomatic peripheral vascular disease, diabetes 
mellitus, and hypertension. Information about coexisting conditions was obtained from 
the TXUNOS file (that file’s data come from the Transplant Candidate Registration 
Form); therefore, the comorbidities used for this study are those that patient had at the 
time of listing for the study transplant.  We did not use data from the CMS-2728 form 
(that also has comorbidity information at the time of onset of ESRD) in order not to 
exclude patients who were not Medicare eligible prior to 1995 (prior to 1995 dialysis 
units and transplant centers were required to fill the Medicare Evidence form only for 
Medicareeligible patients).  To reduce lead time bias, the models were also adjusted for 
total duration of ESRD prior to the follow-up time included in the Cox models.  Unrealistic 
values of the independent variables used in the study were eliminated. In particular, for 
donors and recipients younger than 13 years of age, the United States CDC Growth 
charts were used as a guide for determining valid ranges. The heights and weights of 
recipients and donors age 13 and older were based on the acceptable ranges: height 
(122 to 274 cm), weight (23 to 180 kg). 
Other variables, delayed graft function, episodes of acute rejection, and type of 
immunosuppressive medications were not included in the models.  Delayed graft 
function and acute rejection may represent intermediate outcome rather than the 
confounding factor and therefore, we speculated that adjusting for it might yield false 
negative results (type 2 error: failure to reject null hypothesis).   
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Patients with a prior history of kidney transplant in some subprojects described 
below were analyzed separately and for this subgroup, the following variables were 
added to the analysis: donor type for the transplant immediately prior to the current 
transplant, age at the first transplant, age at the first graft failure, age at transplant 
immediately prior to the current transplant and at graft failure immediately prior to the 
current transplant, time period between last transplant failure and current transplant.  To 
reduce lead time bias, the models were also adjusted for total duration of ESRD. 
 
4.2.4. Statistical analysis 
 
Categorical variables in the subgroups were compared using cross-tabulation.  
Continuous variables were summarized using means and standard deviations.  Kaplan-
Meier graphs and Cox regression models were used for survival analysis.  To avoid 
colinearity between the primary variables of interest, we analyzed these variables in 
separate Cox models.  SAS (SAS Institute, Cary, NC) was used for survival analysis 
(Kaplan-Meier and Cox proportional hazards models), while S-Plus (Insightful, Seattle, 
WA) was used for descriptive statistics and tree-based modeling for data imputation.   
 
4.3. Baseline characteristics 
 
The characteristics of the study population are presented in Table 2. The 
recipients were 60% male, 70% White, and 27% diabetic, with an average age of 43 
years at the time of the study transplant. Roughly one-in-eight (12.6%) had at least one 
prior transplant.  The subset of patients had more than one transplant (retransplants, 
n=11,714). These recipients were 59% male, 78% White, and 16% diabetic, with an 
average age of 38.5 years at the time of the study transplant.  The median time between 
last graft failure and current transplant surgery was 21.9 months; 13.7% had preemptive 
retransplants (n=1,609).  
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Table 2.  Baseline characteristics of the of kidney transplant recipients (n=92,844) at the 





Race (White, African American, Asian, Native American) 70.2%, 23.0%, 3.4%, 0.9% 
Weight (kg) 72.6±17.2
Height (cm) 169.0±13.7




 Cystic disease 7.6%
 Other 24.2%
Comorbidity score2 0.8±0.8
History of diabetes 27.2%
History of hypertension 52.5%
Total duration of end-stage renal disease (yrs) 3.1±3.6
Percent of end-stage renal disease duration time on 
peritoneal dialysis3 
22.8±38.0
Percent of end-stage renal disease duration time on 
hemodialysis3 
67.3±41.5
Percent of total end-stage renal disease duration with 
transplant3 
6.1±20.1




 Peritoneal dialysis 21.8%
 Transplant (dialysis free retransplant) 1.1%
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Predominant renal replacement therapy modality4   
 Hemodialysis 67.3%
 Peritoneal dialysis 22.6%
 Transplant 6.4%
 None 3.6%
Total number of transplants (including the current one) 1.2±0.4
Time on the transplant list (yrs) 1.3±1.1
Peak reactive antibody level (%) 12.1±21.5
Mean reactive antibody level (%) 5.3±14.7
Number of matched HLA antibodies 1.8±1.5
Cold ischemia time (hr) 15.5±8.7
Transplant day of the week5  4.0±1.8
History of previous kidney transplant(s) 12.6%
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Terminal serum creatinine level (mg/dL) 0.9±0.3
















1Continuous variables presented as mean ± standard deviation 
2 The comorbidity score used in our study was calculated based on the following 
coexisting conditions, each of them contributing one point: cardiovascular disease 
(defined in USRDS as symptomatic cardiovascular disease or angina/coronary artery 
disease), symptomatic peripheral vascular disease, diabetes mellitus, and hypertension.   
3 Information obtained from USRDS RXHIST file; due to missing/unknown data and "60 
days rule" convention adopted by USRDS (see text) the total is less than 100%  
4Predominant renal replacement therapy modality defined as a modality used for >50% 
of the duration of end-stage renal disease 
5Transplant day of the week expressed in numbers starting with Sunday (1=Sunday, 
2=Monday, etc.) 
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The ESRD course itself (e.g., the modality of renal replacement therapy [RRT], 
alone or in combination) as a predictor of graft and patient outcomes has not been well 
studied.  Several studies suggest that this pretransplant dialysis modality has an impact 
on patient outcome [114-117].  However, some reports have not shown that long-term 
graft survival is affected by the modality of dialysis treatment [118, 119].  What is 
established is that increased time on dialysis is associated with decreased survival of 
transplant recipients [119].   
The goal of this project was to perform a retrospective analysis of United States 
Renal Data System (USRDS) data to evaluate the role of renal replacement modalities, 
including number of modalities used and their combinations in allograft and recipient 
survival. 
 
4.4.2. Primary variables of interest 
 
The primary variables of interest were those pertinent to RRT from the USRDS 
database: RRT modality immediately prior to current transplant; predominant RRT 
modality during the ESRD course (defined as modality used for >50% of the ESRD 
period; if none of the modalities were used for more than 50%, then predominant 
modality was labeled as “None”); number of different RRTs used; the combination of 
RRT modalities used (e.g., peritoneal dialysis [PD] and hemodialysis [HD] and 
transplant); and the time course during the pretransplant period that the patient was 
treated with a specific RRT modality.  We defined the use of a specific dialysis modality 
using the “60 day rule,” ( the convention adopted by USRDS), stating that a dialysis 
modality must continue for at least 60 days in order to be considered stable, and 
therefore constitute a change in modality.   




4.4.3.1. Baseline characteristics 
The dataset comprised 92,844 records of patients receiving kidney or kidney-
pancreas transplants starting January 1, 1990 and through December 31, 1999.  The 
study population characteristics are presented in Table 2.   
 
4.4.3.2. RRT modality immediately prior to transplant 
A Cox model using HD as a reference demonstrated the following results.  
Having a transplant immediately prior to the transplant of interest without dialysis in 
between was associated with increased risk of graft failure (Hazard Ratio [HR] 1.65, 
p<0.001).  PD as a modality immediately prior to transplant predicts a better graft 
outcome compared to HD (HR 0.97 p<0.05). See Table 3. A similar association was 
found in the subgroup of patients with a previous history of kidney transplant: having the 
transplant as an RRT modality prior to the last transplant without going on dialysis in 
between posed a greater risk of graft failure (HR 1.99, p<0.001) in this subgroup of 
patients.  The protective effect of PD is not significant in this patient subgroup.   
In the analysis of recipient survival in the Cox model using HD as a reference, 
both prior transplant (0.80 p<0.005) and PD (0.94 p<0.001) had protective effects on 
recipient survival compared to HD.  This association was confirmed again in the 
subgroup of patients who had prior transplants, though the difference between PD and 
reference (HD) was not statistically significant (Table 3).   
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Table 3.  Results of Cox proportional hazard model analyzing the role of renal 
replacement therapy in the allograft and recipient survival 1.  
 
Graft survival Recipient survival   
Hazard 
ratio 




95% CI p 
Renal replacement therapy modality 
immediately prior to current 
transplant2 
      
 
        
  Peritoneal dialysis 0.97 0.94 1 <0.05 
 
0.94 0.91 0.97 <0.001 
  Transplant 1.65 1.51 1.8 <0.001 
 
0.8 0.68 0.93 <0.005 
  Unknown 0.92 0.85 1 <0.05 
 
0.87 0.77 0.97 <0.05 
  Lost to follow-up 1.07 1 1.15 0.069 
 
0.9 0.81 0.99 <0.05 
Predominant renal replacement 
therapy modality2 
      
 
        
  Peritoneal dialysis 0.97 0.94 1 <0.05 
 
0.96 0.92 0.99 <0.05 
  Transplant 0.86 0.81 0.9 <0.001 
 
0.82 0.76 0.89 <0.001 
  None 0.9 0.84 0.95 <0.001 
 
0.92 0.85 1 0.063 
Time spent on hemodialysis 
(years) 
1.02 1.01 1.02 <0.001 
 
1.05 1.04 1.05 <0.001 
  >0 to 1 year 1.05 1.01 1.09 <0.05 
 
1.18 1.12 1.24 <0.001 
  >1 to 3 years 1.18 1.13 1.23 <0.001 
 
1.42 1.34 1.5 <0.001 
  >3 years to 10 years 1.18 1.12 1.23 <0.001 
 
1.59 1.5 1.7 <0.001 
  >10 years to 33 years 1.27 1.16 1.39 <0.001 
 
1.77 1.57 2 <0.001 
Time spent on PD (years) 1.02 1.01 1.03 <0.005 
 
1.04 1.03 1.06 <0.001 
  >0 to 1 year 1.04 1.01 1.08 <0.05 
 
1.12 1.07 1.17 <0.001 
  >1 to 3 years 1.08 1.04 1.12 <0.001 
 
1.21 1.16 1.27 <0.001 
  >3 years to 10 years 1.13 1.06 1.2 <0.001 
 
1.33 1.23 1.44 <0.001 
  >10 years to 33 years 1.28 0.99 1.64 0.057 
 
1.43 1 2.04 0.053 
Time spent with prior 
transplant (years) 
0.98 0.97 0.99 <0.001 
 
1 0.99 1.01 0.525 
  >0 to 1 year 0.84 0.78 0.9 <0.001 
 
1.06 0.95 1.19 0.319 
  >1 to 3 years 0.82 0.75 0.9 <0.001 
 
1.08 0.94 1.23 0.291 
  >3 years to 10 years 0.72 0.67 0.78 <0.001 
 
1.08 0.95 1.22 0.24 
  >10 years to 33 years 0.67 0.6 0.75 <0.001 
 
1.12 0.94 1.33 0.217 
Number of different renal 
replacement therapy 
modalities3 
1.04 1.02 1.07 <0.005 
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Table 3 Continued 
Graft survival Recipient survival   
Hazard 
ratio 




95% CI p 
Combinations of renal replacement 
therapy modalities2 
      
 
        
  PD only 0.93 0.9 0.96 <0.001 
 
  0.9 0.86 0.94 <0.001 
  PD+transplant 0.87 0.78 0.97 <0.05 
 
0.98 0.83 1.17 0.86 
  PD+HD 1.09 1.05 1.12 <0.001 
 
  1.1 1.06 1.15 <0.001 
  HD+transplant 0.74 0.69 0.8 <0.001 
 
0.96 0.86 1.08 0.508 
  Transplant only 0.94 0.85 1.05 0.269 
 
0.89 0.75 1.06 0.196 
  PD+HD+transplant 0.73 0.67 0.8 <0.001 
 
1.11 0.98 1.27 0.106 
  None 0.75 0.69 0.81 <0.001 
 
















1 The Cox model represents a multivariate analysis of graft and recipient survival.  To 
avoid colinearity between the primary variables of interest they were analyzed in 
separate Cox models.  Only primary variables of interest are presented in the table.  All 
models were also adjusted for the following covariates: recipient age, gender, race, 
height, weight, history of hypertension, diabetes, recipient comorbidity score, history of 
prior transplant, total duration of ESRD, and total number of transplants, panel reactive 
antibody levels (mean and peak), recipient education level, primary source of renal care 
payment, and citizenship; donor variables: heartbeating donor or not, age, gender, race, 
height, weight, number of matched HLA antigens, and citizenship; and transplant 
procedure variables (day of the week for the procedure, the season and year of the 
transplant, and cold storage time). 
2Hemodialysis is a reference  
3Sixty days rule applied   
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4.4.3.3. Predominant RRT modality 
Predominant RRT modality, defined as RRT modality (used for more than 50% of 
the whole ESRD period) was analyzed in a Cox model in relation to the graft survival. 
Both PD (HR 0.97 p<0.05) and transplant (HR 0.86 p<0.001) had a protective effect for 
the graft survival compared to HD.   
The absence of the predominant modality (each of the modalities were used for 
less than 50% of the duration of ESRD, or no RRT was used) was also associated with a 
lower risk of graft failure (HR 0.90 p<0.001).  These results were illustrated by Kaplan-
Meier plots (Figure 5, Panel A).  In the Cox model, better recipient survival was also 
associated with both PD (0.96 p<0.05) and transplant (0.82 p<0.001) as predominant 
pretransplant RRT modalities.  Those patients who had no predominant modality during 
ESRD course also had better survival compared to HD, though the difference was not 
statistically significant (HR 0.921, p=0.063).  The worst patient outcome associated with 
HD is illustrated by Kaplan-Meier plots (Figure 5, Panel B).  Same trends for graft and 
recipient survival were found in the subgroup of patients with prior transplants. 
 
4.4.3.4. Number of different modalities used 
We calculated the number of different RRT modalities that the patient was 
exposed to during ESRD course using the “60-day rule,” where the change in dialysis 
technique is considered stable, if the patient remained on a new modality for 60 or more 
days (“60-day rule” does not apply to transplant).  We analyzed the Cox model and 
demonstrated that the number of RRT modalities is a significant predictor of graft failure 
(HR 1.04 per additional modality p<0.001) and recipient death (HR 1.11 per additional 
modality p<0.001).  In the separate model in the subgroup of patients with prior 
transplants, the number of modalities was not a significant risk for graft failure, while it 
was for recipient death (HR 1.09 p<0.005).   





Figure 5.  Predominant renal replacement therapy modality and graft (Panel A) and 
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These associations are illustrated by the Kaplan-Meier plots: the increased 
number of modalities is associated with the worsening of graft survival (Figure 6, Panel 
A), the best graft survival being associated with zero pretransplant RRT modalities.  
Similarly, zero modalities used before transplant were associated with the best recipient 
survival, but an increased number of modalities above 1 does not affect recipient 
survival (Figure 6, Panel B). 
 
4.4.3.5. Combination of different RRT modalities 
We considered 8 different combinations of RRT modalities during the ESRD 
course independent of the sequence and number of times patient would return to a 
particular modality: PD only, HD only, transplant only, PD + HD, PD + transplant, HD + 
transplant, all three modalities, and None.  We defined combinations of RRT modalities 
using the “60 days rule” described above.  In the Cox model (“HD only” was used as a 
reference group), any combination or single modality (except for transplant only, PD + 
HD, and None) were better than HD only (Table 2).  In particular, “PD only” was 
associated with HR 0.93 (p<0.001).  PD + HD and None were associated with 
nonsignificantly higher risk.  When patient survival was evaluated, modality combinations 
showing the significant difference with the reference group (HD only) were: PD only (HR 
0.90 p<0.001) and None (HR 0.81, p<0.001) and also PD and HD (1.10 p<0.001).  
When patients with prior transplants were analyzed separately compared to HD alone, 
PD alone was associated with the lower risk of graft failure (HR 0.60 p<0.05), PD + HD + 
transplant was also beneficial (HR 0.79 p<0.005), as well as HD + transplant (HR 0.791 
p<0.005).  When recipient survival was used as an outcome, PD + transplant (HR 0.73 
p<0.05), HD + transplant (HR 0.74 p<0.005), and transplant only (HR 0.62 p<0.0005) 
were associated with the lower mortality risk.  
 
 





Figure 6.  Number of different renal replacement therapy modalities and graft (Panel A) 
and recipient (panel B) survival. The increased number of modalities is associated with 
the worsening of graft survival, with the best graft and recipient survival associated with 
zero RRT modalities (preemptive kidney transplant).   
  48 
 
4.4.3.6. Number of years on specific dialysis modality 
The Cox model discussed in this section was not adjusted for total duration of 
ESRD to avoid colinearity with the primary variables of interest.  The duration of both 
dialysis modalities was associated with a higher risk of graft failure.  Each year of PD is 
associated with HR of 1.02 (p<0.005), while each year of HD is associated with HR of 
1.02 (p<0.001).  On the other hand, the number of years with functioning graft in the past 
had a protective effect on a current graft survival (HR 0.98 p<0.001).  In the subgroup of 
patients with prior transplant, the same trend is true, but the association between the 
duration of PD and graft failure is not statistically significant.  We performed the same 
analysis for the recipient survival and demonstrated similar associations.  The longer the 
patient was on HD (HR 1.05 p<0.0001) or PD (HR 1.04 p<0.005), the higher the risk of 
dying, while number of years with prior transplant did not make a significant difference.  
Recipient survival in the subgroup of patients with prior transplant was also analyzed.  
The number of years on PD (HR 1.05 p<0.005) or HD (1.04 p<0.001) was associated 
with greater risk of recipient mortality, while the number of years with a functioning graft 




In general, prior studies comparing different renal replacement modalities in 
relation to the transplant outcome were based on the small datasets [115, 120], 
evaluated short-term rather than long-term outcome [115, 117, 121, 122], have not 
studied combination of the RRT modalities, or were done 10-20 years ago, before 
significant changes in the immunosuppressive regimens [120-124].  Most of the studies 
examined the graft outcome only, and not patient survival.  In addition, most of the 
authors evaluated the role of RRT modality immediately prior to the transplant rather 
than predominant modality as a primary variable of interest.  Patients who were on PD 
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for a number of years and were switched to HD immediately prior to transplant would be 
classified as a HD in these studies, which introduces a significant degree of 
misclassification bias.   
 Previous studies on short-term transplant outcome have yielded somewhat 
conflicting results.  Higher rates of early graft failure were associated with PD as 
demonstrated by [125].  In the report by Bleyer et al. [117],  the authors evaluated 
delayed graft function after deceased donor transplant based on dialysis modality 
immediately prior to transplantation and found an association between HD and delayed 
graft function.  Similar results were demonstrated by other authors [115, 116, 125-127].  
Vanholder et al. also demonstrated the advantage of PD for short-term outcome: 
patients on PD have reduced incidence of acute renal failure [115].  PD is recommended  
as an initial modality in patients who plan a kidney transplant within 2-3 years [128]. 
Though in one report there was no association between dialysis modality and 
graft thrombosis [129], in several other studies, increased incidence of graft thrombosis 
associated with PD compared to HD was reported [33, 125, 130-132].  Higher rates of 
graft thrombosis in PD patients might be because hypercoagulable states are not so 
readily detected in PD patients as in HD patients.  Higher rates of acute rejection were 
associated with PD [115]; however, in other reports, the rate of acute rejection was not 
found to be different between patients on PD vs. those on HD before the transplant [117, 
124, 127, 132].  Peritoneal dialysis was associated with a higher rate of posttransplant 
infection compared to patients on HD in some reports [133], but in other ones, the rate of 
infection between PD and HD was found to be similar [115, 134] or lower in patients with 
pretransplant PD [135]. 
When long-term outcome (1 and 5 years) was studied, no difference between 
dialysis modalities was reported [124].  Similarly, PD and HD showed similar 1-year 
outcome in a report by Donelly in the mid-80s [122].  In a small case-control analysis, 1- 
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year outcome of transplantation in patients on continuous ambulatory peritoneal dialysis 
is not significantly different from that in HD patients with similar clinical characteristics 
[120].  Similar long-term graft and patient survival is achieved independent of the 
modality of dialysis prior to transplantation in a retrospective analysis of the first 
cadaveric graft.  Graft and patient survival cases were identical in HD and continuous 
ambulatory peritoneal dialysis groups (5-year graft survival: continuous ambulatory 
peritoneal dialysis 67%, HD 66%; 5-year patient survival: continuous ambulatory 
peritoneal dialysis 88%, HD 87%) [123].  No difference in long-term outcome between 
patients treated with PD compared to those on HD was demonstrated in other studies 
[121, 127, 136, 137].  Snyder et al. [125] compared long-term transplant outcome 
between PD and HD and demonstrated that compared to pretransplant HD, death 
censored long-term graft failure was 15% higher in patients on PD and short-term graft 
failure was 33% higher.  Their analysis was based on 22,776 Medicare beneficiaries with 
kidney transplant.  Compared to our analysis,  the Snyder et al. study [125] used a 
smaller number of patients, shorter follow-up (3 years), and some baseline 
characteristics of the study population were different from ours (pediatric patients and 
those with prior history of transplant were excluded).  These authors studied 
pretransplant dialysis modality (based on UNOS form) adjusted for the dialysis modality 
change as a binary variable, while we evaluated the role of both pretransplant and 
predominant dialysis modality as well as the number of modalities used and their 
combinations. 
Our study, when compared to HD and/or PD immediately prior to transplant, 
demonstrated a protective effect on the graft and recipient survival.  Even though the 
effect size associated with PD is modest, we disprove previous reports claiming a higher 
long-term risk associated with PD.  We evaluated the role of the predominant RRT 
modality during the ESRD course.  Peritoneal dialysis, transplant, and preemptive or 
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very short course dialysis had a protective effect for the graft and recipient survival.  This 
approach again confirmed an advantage for allograft and recipient survival of PD over 
HD as a modality immediately prior to transplant and as a predominant modality during 
the ESRD course.  Though statistically significant, the effect of the size of the dialysis 
modality is quite limited (HR 0.97 and 0.94 for graft and recipient survival, respectively, 
for PD as an RRT modality immediately before transplant; and HR 0.97 and 0.96 for 
graft and recipient survival, respectively, for PD as a predominant RRT modality 
compared to HD).  For comparison, the effects of size of other predictors of the graft and 
recipient survival evaluated in our analysis were as followed: recipient age (HR 1.01 p 
<0.001; HR 1.04 p<0.001 per year of life for graft and recipient survival, respectively); 
recipient history of diabetes (HR 0.96 p=0.48; HR 1.11 p=0.107 for graft and recipient 
survival, respectively); recipient comorbidity score (HR 1.1 p <0.001; HR 1.26 p <0.001 
per unit increase in score for graft and recipient survival, respectively); living donor as 
compared to deceased donor (HR 0.68 p <0.001; HR 0.67 p <0.001 for graft and 
recipient survival, respectively); donor age (HR 1.01 p<0.001; HR 1.01 p <0.001 per year 
of life for graft and recipient survival, respectively);  and number of HLA matched 
antigens (HR 0.94 p<0.001; HR 0.96 p <0.001 per antigen matched for graft and 
recipient survival, respectively).   
The number of RRT modalities used during ESRD course is a significant 
predictor of graft failure and recipient death.  Almost any single RRT modality or their 
combinations were associated with better graft and recipient outcome than with HD only.   
The mechanism of the outcome observed in our analysis is not completely clear.  
Residual renal function that might be better preserved in patients on PD may contribute 
to better preservation of kidney function after transplant [138].  One can hypothesize that 
the degree of residual renal function is more important for the graft and recipient 
outcome than either PD or HD modality.  Unfortunately, we did not have information 
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about the residual renal function for the whole study population.  Answering this question 
could be a subject of another research project.  Furthermore, body mass index and 
degree of hypervolemia might be different in the PD and HD patients and therefore 
confound the results.  The rate of posttransplant infections associated with HD might be 
higher as compared to PD [135].  In addition, there are some indications that HD 
membranes and vascular access might cause sensitization in transplant candidates 
[139].  It has been shown that HD patients demonstrate the elevation of natural killer 
cells [140] and production of cytokines [141].  Other immunological differences might 
exist between HD and PD patients.  It was postulated that PD modifies the population of 
T-helper (Th) cells with an increase in the percentage of Th2 cells and by a normal 
percentage of Th1 cells [142].  Th2 cells produce inteleukin-4 and inteleukin-10, which 
inhibit interferon-gamma secretion and cell immunity [143], while increased Th2 cell 
fraction may provide additional immunosupression.   
Potential selection bias should be considered when interpreting the results of this 
study.  We speculated that the decision regarding dialysis modality is made based on 
patient’s age, diabetic status, comorbidity, ability to learn the technique, prior history of 
abdominal surgeries, the distance to dialysis center, and the status of vascular access.  
Adjusting our multivariate models for recipient age, diabetic status, comorbidity index, 
socioeconomic status (indicated by educational level, primary source of pay for renal 
care, and citizenship), and duration of ESRD should considerably reduce the selection 
bias.  We recognize that some factors not included in the models (e.g., exhausted 
vascular access) might force the selection of the dialysis modality and confound the 
results.  Though our models were carefully adjusted for pertinent covariates, HD and PD 
populations are different in our study as well as in other reports.  For example, it was 
demonstrated that PD patients are more likely to be transplanted than HD patients both 
in the group of adult patients [125], and to a lesser extent in the group of pediatric 
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patients [144].  One can speculate regarding the causes of this discrepancy, that certain 
demographic characteristics and potentially the more assertive personality of the PD 
patient versus the HD patient might make the former more aggressive in pursuing 
transplantation.  Indeed, in our study population, PD was a pretransplant RRT modality 
in 21.8% and predominant RRT modality in 22.6% of patients, while in the dialysis 
population, PD patients comprised less than 15% [145]. To explain this phenomenon, 
Snyder et al. [125] proposed that there is a perception among physicians that PD 
patients may be better candidates for transplant [115, 128] and therefore, there exists a 
selection bias, where potential transplant candidates are more likely to be placed on PD 
rather than on HD.  Other potential shortcomings should be considered in interpreting 
results of this retrospective data analysis.  Retrospective analysis of data registry 
demonstrates the association (but not necessarily the causative relationships) between 
the primary variables of interest and the outcome.  The sequence of PD and HD for 
those patients receiving both has not been evaluated in this study and might be a 
subject of future research.   
In conclusion, our results suggest that compared to PD, hemodialysis as a RRT 
modality immediately prior to transplant or as a predominant RRT modality during ESRD 
course, used alone or in combination with other RRT modalities, is associated with 
increased risk of graft failure and recipient death. An increased number of RRT 
modalities used during ESRD course is associated with worsening of the graft and 
recipient survival.  Peritoneal dialysis is a reasonable choice of renal replacement 
therapy and should not be avoided in the transplant candidates [66]. 
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4.5. The role of previous history of kidney transplant 
4.5.1. Introduction 
In general, preemptive transplant (i.e., without exposing the patient to dialysis) 
seems to be advantageous for graft survival [32, 64, 146].  The length of time on dialysis 
prior to the first transplant is a predictor of the graft and recipient survival. However, a 
relatively short duration of dialysis does not change either graft or recipient outcome 
[64].  It is unclear if the general advantage associated with preemptive transplantation 
holds for patients with a prior kidney transplant.  There is no clear evidence in the 
literature whether patients who failed a previous transplant should be retransplanted 
preemptively or be allowed to “cool down” on dialysis before the next transplant.  Since 
the role of renal replacement therapy in the period between graft failure and a follow-on 
transplant is understudied in this important and growing set of patients, the aim of this 





The following independent variables were collected: history of transplants prior to 
the study transplant, total number of transplants, renal replacement therapy immediately 
prior to the study transplant, and time between the last allograft failure and the study 
transplant surgery.  
Our definition for preemptive retransplant included all patients with dialysis-free 
retransplant (n=788) or those who had <7 days between a graft failure and a 
retransplant (the data to calculate this variable were complete for the subset of patients 
with prior kidney transplants) (n=1,609).  The latter group was broader and in fact 
included all 788 patients with dialysis-free retransplant; therefore, the number of patients 
with preemptive transplant was 1,609.  Dialysis-free retransplant was assumed for any 
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case where the renal replacement therapy (RRT) immediately prior to transplant was 
reported itself as “transplant.” RRT modality prior to transplant was derived from the 
RXHIST USRDS file. We considered this source more reliable than the PRTXDIAL 
variable from the UNOS file (the latter had > 30% missing values, where the RXHIST file 
only had about 6% missing or unknown values).  The time between the last graft failure 
and the most recent transplant was calculated as a difference between the most recent 
transplant surgery date and the failure date of the graft prior to the most recent one. This 
variable was complete for the subset of patients with prior kidney transplants.  
Separate Cox models were used to correct for colinearity between the primary 
variables.  In particular, these pairs of variables were considered to have high degree of 
possible colinearity and were evaluated in a separate Cox model: history of prior 
transplant as a binary variable and total number of transplants; time after last graft failure 
and preemptive transplant as a binary variable; time after last graft failure and duration 
of ESRD course; and duration of ESRD course and duration of previous graft function. 
Use of Mycophenolate Mofetil (MMF) in the maintenance antirejection regimen was used 




4.5.3.1 The role of prior transplants  
 
The role of previous transplants was analyzed for the entire dataset (n=92,844), 
and a total of 11,714 patients had been retransplanted.  The Kaplan-Meier curves 
representing the role of prior transplant in the graft and recipient survival are presented 
in Figure 7 for any transplant history (Panels A and B) and for the total number of prior 
transplants (Panels C and D).  The analysis represented by Kaplan-Meier graphs is not 
adjusted for confounding factors and suggests that patients with prior transplants do 
significantly better than those with the first transplant, and that patients with a total of 2  
































Figure 7.  Kaplan-Meier analysis of the graft (Panel A, χ2=218.4, p<0.001) and recipient 
(Panel B, χ2=22.5, p<0.001) survival in patients with and without prior kidney transplant 
and association of the graft (Panel C, χ2=525.1, p<0.001) and recipient (Panel D, 
χ2=57.4, p<0.001) survival with total number of transplants.  Log-Rank test was used to 
test strata homogeneity. 
 















































Figure 7 continued 
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transplants might survive longer than the recipients of a single transplant.  However, 
when the analysis is adjusted for confounding factors in the Cox model (described 
below) the association between prior transplant and recipient survival loses its statistical 
significance.   
In the Cox model, any history of prior transplant was associated with a significant 
increased risk of failure of the study graft (Hazard Ratio [HR] 1.24, p<0.001) but not the 
risk of recipient death; and the risk of graft failure (but not the recipient mortality)  
increases as the number of past transplants increases (increase in HR of 1.35 per 
transplant, p<0.001).  The longer duration of prior graft survival but not the type of the 
graft (living vs. deceased) had a protective effect on the consecutive graft and recipient 
survival. 
 
4.5.3.2. Preemptive retransplant 
 
Altogether, 1,609 or 13.7% of all retransplanted patients had preemptive 
retransplants.  Using the Cox model presented in Table 4, preemptive retransplant was 
associated with an increased risk of graft failure (HR 1.36, p<0.001) but not of recipient 
mortality (HR 1.02, p=0.77).  The shape of the Kaplan-Meier curves suggests early graft 
failure as contributing to the poor graft survival in the recipients of preemptive 
retransplants.  Therefore, we repeated the Cox analysis after eliminating the recipients in 
whom graft survived 0 days (primary nonfunctioning graft) (n=555) and demonstrated 
similar results.  The risk of preemptive retransplant for graft failure had a HR of 1.29 
(p<0.001, 95% CI 1.13 - 1.46), and the risk of recipient mortality had a HR of 1.12 
(p=0.084, 95% CI 0.984 - 1.283).  Furthermore, we analyzed the subgroup of patients 
with previous graft survival of ≥90 days after excluding recipients with previous graft 
survival of <90 days.  In the remaining dataset (n=10,053), the risk of preemptive  
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Table 4.  Results of a Cox proportional hazard model to evaluate the role of variables 
describing prior transplant characteristics.  Variables analyzed in all recipients of 
retransplant (n=11,714) and in the subset of patients with a single prior transplant 
(n=10,070). 
 
  All retransplant patients Recipient of single 
retransplant 











Graft failure          
1. Preemptive retransplant = 
"yes"2 
1.36 (1.21-1.54) <0.001 1.59 (1.23-
2.04) 
<0.001 
2. Time between last graft failure 







3. Donor type for prior transplant      
 Living3 0.99 (0.93-1.07) 0.8488 0.99 (0.91-
1.06) 
0.684 
  Missing3 1.05 (0.94-1.17) 0.432 0.87 (0.71-
1.08) 
0.202 
4. Duration of ESRD and fraction of time with transplant 
 Total duration of ESRD 
(years) 
0.99 (0.98-1.00) 0.012 0.99 (0.98-
1.00) 
0.019 
















        
1. Preemptive retransplant = 
"yes"2 
1.02 (0.90-1.15) 0.77 0.83 (0.69-
0.99) 
0.037 
2. Time between last graft failure 








3. Donor type for prior transplant      
  Living3 0.90 (0.81-1.00) 0.055 0.92 (0.82-
1.03) 
0.143 
  Missing3 1.11 (0.95-1.29) 0.185 0.92 (0.69-
1.23) 
0.576 
4. Duration of ESRD and fraction of time with transplant 
 Total duration of ESRD 
(years) 
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Table 4 continued 
 
  All retransplant patients Recipient of single 
retransplant 



































1Separate models were fitted for co-linearity-related factors.  Each model shown in the 
table is adjusted for the following list of covariates: recipient age, gender, race, height, 
weight, history of hypertension (HTN), diabetes, comorbidity index, total duration of ESRD 
prior to the follow-up time included in the Cox models, education level, primary source of 
pay, citizenship, history of prior transplant, total duration of ESRD, and total number of 
transplants, type of donor (cadaveric or living), heartbeating donor or not, donor age, 
gender, race, height, weight, and citizenship, day of the week the transplant was done, 
year of the transplant, number of matched HLA antigens, and cold storage time. 
2Preemptive retransplant define as “Yes” if renal replacement modality immediately prior to 
the study transplant was “transplant” or the time between last graft failure and the study 
transplant was <7 days. 
3 Deceased donor is the reference. 
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retransplant for the graft survival (HR 1.26, p<0.005, 95% CI 1.09-1.46) and recipient 
survival (HR 1.24, p=0.027, 95% CI 1.03 – 1.50) was substantially increased. 
Analysis of the subgroup of patients with only one retransplant (history of single 
graft failure in the past, n= 10,070) yielded similar results for the graft survival (HR 1.59, 
p<0.001), while the recipient survival associated with preemptive retransplant was 
significantly better (HR 0.83, p<0.05).   
 
4.5.3.3. The effect of waiting time for retransplant 
To examine the effect of the waiting time for the retransplant, we examined the 
role of the time between last graft failure and the most recent transplant (median time 
was 21.9 months).  Increasing this time interval had significant association with the 
adverse outcome of the most recent graft (only in patients with a single retransplant), 
and the risk of patient death (Table 4). 
 
4.5.3.4. Stratification by the transplant era   
Major changes in immunosuppressive medications were unveiled in the mid- 
1990s (e.g., tacrolimus was approved for liver transplantation in 1994 and was used "off-
label" in kidney transplant soon after its release; Mycophenolate Mofetil and Neoral were 
introduced in 1995).  Therefore, we report a stratified survival analysis by the use or 
nonuse of Mycophenolate Mofetil (MMF) as a surrogate for a transplant era. In 5.6% of 
the population, the information about use of MMF was missing, and the remaining 
dataset was used for analysis.  In the remaining dataset of single and multiple kidney 
transplants (n=87,652), 28,360 (32.4%) patients were on MMF, while 59,292 (67.6%) 
were not.  In the dataset of patients with retransplant(s) with information of MMF use 
nonmissing (n=11,565), 3,693 (31.9%) patients were on MMF, while 7,872 (68.1%) were 
not (Tables 2 and 4).  Most of the associations observed in the entire dataset were also 
present in both the MMF(+) and MMF(-) strata. 
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4.5.3.5. Characteristics of the patients who received preemptive  
retransplants 
 
We evaluated the subgroups of preemptive retransplant patients and 
nonpreemptive retransplant patients to assess their potential distinguishing 
characteristics.  We evaluated the percent of the whole ESRD course prior to the study 
transplant spent on dialysis or with another transplant.  Patients with preemptive 
retransplants had a greater percentage of their pretransplant ESRD course up to the 
time of the study transplant spent with transplant (50.6%±43.6% vs. 42.0%±32.6% in 
nonpreemptively retransplanted patients, p<0.001), but a lower percentage time spent 
on hemodialysis (34.6%±38.1% vs. 38.0%±31.9% p<0.001) and peritoneal dialysis 
(9.4%±21.8% vs. 11.5%±21.5% p=0.083).  The duration of the ESRD was longer in 
patients without preemptive retransplant.  Thirty percent of the preemptive retransplant 
patients had living donors, while only 17.6% of those without preemptive retransplant 
had living donors. 
 
4.5.4. Discussion  
 
The prediction of renal transplant recipient and graft survival is an important 
clinical issue, especially in view of the growing shortage of donor organs[147].  
Traditionally, ESRD patients would take a course of hemodialysis (HD) or peritoneal 
dialysis (PD), or both, possibly followed by one or more transplants.  Increasingly, 
patients are opting for transplantation as the very first ESRD treatment modality, a 
choice labeled “preemptive transplant.” Much of the enthusiasm for preemptive 
transplantation stems from reports that they are advantageous for graft and recipient 
survival [22, 32, 146, 148], while increased time on dialysis prior to a transplant is a 
predictor of negative short-term graft outcome [32, 64].   
More specific to this study, factors that influence retransplant graft survival have 
been identified as well.  Notable roles have been identified for the period of survival of 
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the previous graft, the use of cyclosporin A, the level of preformed antibodies, the ESRD 
cause (in particular diabetes and analgesic nephropathy), and the patient's gender [149].  
Gjertson recently delineated the top five factors affecting 1-year regraft survival rates 
(transplant center, duration of first graft function, donor age, recipient's body mass index, 
and year of transplant) [150].  He also showed that long-term allograft outcome 
depended on donor age, transplant center, recipient age and race, and donor 
relationship.   
In this project, we demonstrated a better graft outcome, but not recipient survival, 
with the first transplant compared to the patients with prior history of transplants; the 
latter had a 24% higher risk of graft failure.  Each additional transplant in the past 
incrementally increased the risk of graft failure.  Since retransplantation patients occupy 
an ever-increasing portion of the transplant waiting list, it is reasonable to ask whether 
preemptive retransplantation should be added to these lists of important predictors.  
While numerous studies, including one by our group [64], demonstrated the positive 
association between preemptive first kidney transplant and graft and recipient survival, 
the effect of preemptive retransplantation on the graft and recipient outcome has not 
been established.   
Our data suggest that the risk of graft failure is actually higher in preemptive 
retransplant patients by 36%.  We did not find any association between the recipient 
survival and preemptive retransplant, except for the subgroup of patients with a single 
retransplant, where the risk of death decreased by 17%.  The result that preemptive 
retransplant decreases graft survival but increases recipient survival in the subgroup of 
patients with single retransplant is somewhat counterintuitive; better allograft outcome 
should translate into better patient survival.  One can imagine that lead time bias, which 
favors healthier recipients at the outset, may play a role here. This effect would 
represent a true bias rather than true improvement in the survival.   
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Interestingly, the recipients of the nonpreemptive transplant in our study on 
average had significantly more kidney transplants in the past compared to recipients of 
the preemptive retransplant.  Also, there is a greater proportion of the deceased donors 
in the recipients of nonpreemptive retransplant.  Furthermore, the comorbidity score is 
higher and the total duration of ESRD is significantly greater in the recipients of the 
nonpreemptive retransplant, which should also adversely affect their outcome.  The 
comparison between the groups does indicate that the recipients of the nonpreemptive 
retransplant are at a disadvantage in regards to the classic predictors of the clinical 
outcome.  Despite that, however, the multivariate model, when adjusted for such 
variables, demonstrated a better outcome in nonpreemptively transplanted patients with 
respect to the graft survival.  Although apparently counterintuitive, this discrepancy is 
fairly common when the results of simple group comparison are considered separately 
from multivariate modeling.  The multivariate model takes the disparity that exists 
between the study groups into account and makes an adjustment for it, so these 
differences become irrelevant to the final outcome of the modeling.  The results of the 
Cox model therefore should be interpreted as if the study populations were equal in 
regard to the baseline characteristics included in the model. 
We also found that waiting time after the previous graft failure has an association 
with the worse graft survival in the recipient of single retransplant and with recipient 
survival in the whole patient population.  However, the effect size of this association is 
relatively small, and since the recipient survival is calculated as a time period starting at 
the transplant event; latter association might be confounded by the lead time bias (i.e., 
patients with preemptive retransplant might have an advantage over those waiting for 
retransplant simply because their clock started earlier).   
Also, to reconcile the better graft survival associated with shorter waiting time 
and worse survival associated with preemptive retransplant, one might imagine that a 
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relatively short period of dialysis between the transplants might be beneficial in 
comparison to preemptive retransplant, while longer time on dialysis might in fact be 
somewhat detrimental.  However, the optimal time on dialysis before retransplant was 
not evaluated in this study.   
Our findings that suggest that preemptive retransplantation is associated with 
worse graft outcome seem to contradict the prior reports of a beneficial effect of the first 
transplant on the graft survival [32, 64, 146].  The question is why preemptive transplant 
is good for the first kidney transplant, but negatively affects the outcome of the 
consecutive transplants.  We hypothesized that this phenomenon could be explained by 
at least several mechanisms based on the difference between the first and subsequent 
transplants.  Recipients of retransplant have been exposed to immunosuppressive 
medications for a period of time, and might have accumulated additional comorbidities, 
as well as experienced side effects of the medical treatments.  The effect of dialysis on 
T-cell activity [140-143] and also the withdrawal of immunosuppressive medications with 
subsequent recovery of the immune system may be the mechanisms of the positive 
effect of the dialysis on subsequent graft outcome.  Hypothetically, the discontinuation of 
the immunosuppressive medications and recovery of the immune system in between 
transplantations might be an important factor in reducing the risk of viral infections and 
malignancies.   
Furthermore, to explain the negative role of preemptive retransplantation, we 
hypothesized that better clearance of toxic products and drug metabolites might be 
achieved with dialysis as compared to the failing kidney allograft, so that patients with 
failed graft receiving the preemptive retransplant might be more “uremic” at the time of 
transplantation than those who were dialyzed prior to retransplantation.  It is also 
possible that patients with failing graft might try to hold on to the poorly functional kidney 
and delay the initiation of dialysis.  By the same token, patients with failing graft might be 
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in general more “uremic” than those with native kidney failure, which would explain the 
opposite effect of the preemptive transplantation on the graft survival in recipients of the 
first vs. subsequent transplantations.  
 It is worth mentioning that since using the year of the transplant as an indicator of 
transplant era may introduce bias in the statistical analysis, we selected the use of MMF, 
that came on the market in the mid-90s, as a surrogate of the transplant era.  Evaluating 
particular immunosuppressive medications was not the focus of our investigation.  Since 
MMF is only an indicator of the transplant era, we do not necessarily think that it has 
direct effect on the outcome.  However, the question remains, why is it that in patients 
transplanted in the late era (on MMF) the negative effect of the preemptive retransplant 
is not statistically significant?  Since the hazard ratio between the groups is very similar, 
the nonsignificant effect in patients on MMF may simply be a reflection of the smaller 
sample size (among patients with retransplant, 3,693 were on MMF and 7,872 patients 
were not on MMF). 
Finally, since this study was based on the analysis of the large dataset, there are 
some issues in interpreting the results that need to be pointed out.  The power of the 
large amount of data leads to the small and clinically nonsignificant associations still 
demonstrating statistical significance in the analysis.  Therefore, the associations with 
the borderline p value (<0.05), while technically significant, should be interpreted with 
caution.  
Also, in this analysis, only patients who survived from the graft failure to the next 
transplant were included in the nonpreemptively transplanted group, which potentially 
introduces a survivor bias.  In other words, the study excludes those patients who were 
transplanted once, failed the graft and died while being on the waiting list, before getting 
the next graft.  That potentially may allow for selection of the healthiest recipients in the 
group with nonpreemptive retransplants.  Multivariate models adjusted for the specific 
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covariates such as comorbidity index may reduce this bias, but it is certainly problematic 
to exclude patients who died on the waiting list from the analysis altogether.  We 
considered including patients with failed graft who were on the waiting list for 
retransplant into the analysis and classifying them as nonpreemptive retransplant.  
However, that would introduce additional problems: some of the patients on the waiting 
list might have never been transplanted for the reason other than death; also, the 
analysis of the graft outcome for this subpopulation would have been impossible 
because the retransplants have never happened.  Therefore, the analysis was done 
based only on the patients who received the retransplant, while those who could 
potentially receive it, but did not survive, were excluded.  Therefore, the results of the 
study should be interpreted with caution due to the potential survivor bias, where only 
patients who survived from the last graft failure to the next transplant were included in 
the study.  In other words, regarding the recipient survival, the results of the study should 
be interpreted as applicable only to those patients who survived to retransplant. One 
should also keep in mind the potential residual survivor bias (even after adjusting for 
comorbidity index) while interpreting the results of the graft survival.   
With the potential caveats associated with retrospective data analysis, these 
results suggest that preemptive retransplantation is associated with increased risk of 
graft failure, while longer time on dialysis in between transplants is associated with 
negative effect upon graft and recipient survival in most patient subgroups.  The optimal 
time in between graft failure and retransplant was not evaluated in this study.  This 
knowledge is important for future construction of the predictive model of long-term graft 
outcome [65]. 
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While preemptive transplant would appear to have an advantage over traditional 
therapy, it is unclear if this represents a negative effect intrinsically associated with 
dialysis or the fact that patients who had a transplant after dialysis generally have a 
longer history of ESRD or have accumulated more comorbid conditions.  Aside from 
prolonging the ESRD course, suggested mechanisms that may account for the 
worsening outcome by exposure to dialysis include increased rate of acute rejection, 
delayed graft function, vascular access complications, and various immunological 
mechanisms[148, 151].   
This study addresses several factors that confounded earlier comparisons of 
dialysis duration to preemptive transplant. Lead-time bias, which occurs because 
candidates for preemptive transplants have better residual kidney function than patients 
already on dialysis, is a variable rarely accounted for in previous work. Categorical 
dialysis modeling strategies, where dialysis is modeled as a categorical variable (e.g., 
the patient was on dialysis or not, or the patient had dialysis for 0-175 days, 176-365 
days, etc.) can obscure subtle or moderate factors influencing outcomes that cannot be 
resolved when patients are lumped together in a few, large groups.  Lastly, 
socioeconomic variables are often ignored in previous studies, even though it has been 
shown that educational level and ethnicity are predictors of receiving a preemptive 
transplant in the first place[146].  An important question remains: are there subgroups of 
patients who might have better outcomes if they received short-course dialysis before 
transplant (e.g., patients with renal failure awaiting transplant, for whom the graft is not 
yet available or those with overt uremic complications where dialysis prior to transplant 
might improve their pretransplant health status)?   
 




4.6.2.1. Baseline characteristics 
In this study, recipients were 44.1±14.3 years old, 60.5% male, 69% White/24% 
African American, 29% diabetic, 49% hypertensive, and had ESRD an average 2.2±2.2 
years prior to transplantation.  Kidney donors were 34.6±15.6 years old, 56% were 
males, 82% White/11.9% African American, and 25.7% living donors.  
 
4.6.2.2. Duration of ESRD and graft survival 
The Kaplan-Meier plot shows that graft outcome worsens as the duration of 
ESRD increases, supporting the results of earlier studies. The Cox models also 
demonstrated a modest overall increase in graft failure as ESRD duration is prolonged: a 
2% increase in risk per year overall (hazard ratio[HR], 1.02 per year, p<0.001).  Analysis 
stratified by the donor type demonstrated the same results for cadaveric and living 
donors.   
An important pattern in the relationship between short-tem ESRD and transplant 
outcome emerges when pretransplant ESRD duration is analyzed with a fine time 
granularity (i.e., 0-14 days, 15-60 days, 61-180 days, 181-365 days, 1-2 years, 2-3 
years, 3-5 years, and >5 years).  A longer course of ESRD was indeed associated with a 
higher risk of graft failure, although the difference became statistically significant only 
after 180 days.  The hazard ratio of graft failure increases from this point in a nearly 
linear fashion, until ESRD duration reaches 3-years, when there is no further increase 
(Figure 8).  Analysis stratified by the donor type yielded similar results for both cadaveric 
and living donors.  To evaluate a potential difference in the association of ESRD duration 
with graft outcome between different dialysis modalities, we stratified the Cox model by 
the predominant dialysis modality.  We found that the association between ESRD  
 




Figure 8.  Hazard ratio of the graft failure in different categories of the pretransplant 
ESRD duration.  Compared to the reference (ESRD duration ≤14 days), the hazard ratio 
of graft failure became significant only after 180 days of pretransplant ESRD.  The 
hazard increased from this point in a linear fashion, until the ESRD duration reached 3 
years, when there was no further increase in the risk of graft failure. 
 
 
duration and graft survival were similar between HD (HR 1.02 per year, p<0.001) and PD 
(HR 1.03 per year, p<0.001). 
 
4.6.2.3. Duration of ESRD and recipient survival  
(calculated from the time of transplant) 
 
The Kaplan-Meier plot shows that a longer duration of ESRD was also 
associated with poorer recipient survival.  In the Cox models, overall recipient survival 
decreased with increased duration of ESRD for all patients (HR 1.04 per year, p<0.001) 
as well as recipients of cadaveric (HR 1.04 p<0.001) and living kidneys (HR 1.06 
p<0.001) analyzed separately.  When ESRD duration was categorized into finer time 
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blocks, the higher risk of recipient mortality only became significant when ESRD duration 
reached 1-year (HR 1.35, p<0.05).  From that point, the hazard increased linearly 
(Figure 9).  Separate analysis of the cadaveric kidney recipients yielded similar results; 
in the recipients of living kidney, the effect of ESRD duration on survival became 
significant at 181-365 days (HR 1.98 p<0.05).  When Cox analysis was stratified by the 
predominant ESRD modality, the overall results were similar between HD (HR 1.04, 
p<0.001) and PD (HR 1.07 p<0.001).   
 
4.6.2.4 Duration of ESRD and recipient survival (calculated  
from the time of onset of ESRD) 
 
To avoid lead time bias, analysis was also performed with recipient survival 
calculated from the time of ESRD onset rather than from the time of transplant surgery.   
Kaplan-Meier curves are flat for the time that the patient remained on dialysis 
pretransplant, since only patients who survived until transplant are evaluated.   
The curves represent different durations of the follow-up, where the longest duration was 
in the group which was on pretransplant dialysis for the longest time.  On visual 
examination, the slopes of the Kaplan-Meier curves seem to be similar in those patients 
who received a kidney transplant after ≤14 days, 15-60 days, or 61-181 days of dialysis.  
Patients who received the kidney 181-365 days after being on dialysis had a faster rate 
of decline, and those who were on dialysis for more than a year had the fastest rate of 
graft loss (including those who received a kidney after being on dialysis for >5 years).  In 
the Cox models, when the duration of ESRD was analyzed as a continuous variable, 
longer ESRD duration was associated with a better recipient survival (HR 0.85 per year, 
p<0.001).  There was no significant advantage in recipient survival with increased 
duration of ESRD when the latter is analyzed as a categorical variable until the ESRD 
duration reached 3 years and greater.  This better outcome was likely to be at least 
partly attributed to survival bias.  
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Figure 9.  Hazard ratio of the recipient mortality in different categories of the 
pretransplant ESRD duration.  Compared to the reference (ESRD duration ≤14 days), 
the hazard ratio of the recipient death became significant only after 1 year of 





The literature on the association between preemptive transplantation and ESRD 
duration versus survival is rich and at times inconsistent.  Recent reports have 
suggested that increased duration of pretransplant ESRD is associated with poor graft 
and recipient outcome [117, 137].  While preemptive transplant without the patient going 
on dialysis at all has been shown to be advantageous to the graft survival in several 
studies[32, 146, 148], some of these studies examined the time on dialysis only as a 
binary variable[146, 148].  
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Meier-Krische [32] reported that longer waiting time on dialysis was found to be a 
significant risk factor for death-censored graft survival and patient death for those 
subjects with a functioning graft after renal transplantation.  However, the smallest 
category of dialysis duration authors analyzed was 0-6 mos.  This particular duration of 
dialysis worsened graft survival, but has not worsened patient survival.  
Previous studies have usually calculated recipient survival from the time of 
transplant to the time of patient death.  This type of analysis may introduce a lead time 
bias, in which patients with shorter ESRD duration have a starting time advantage; in 
effect they are healthier by definition.  Additionally, residual kidney function may 
confound the result of these studies, as those with shorter duration of ESRD are likely to 
have better preserved kidney function[152]. 
To address the lead time bias, we also calculated recipient outcome  based on 
the time of onset of ESRD, instead of the time of transplant. When the recipient survival 
was calculated from the time of ESRD onset, the survival had a sharper rate of decline 
only when the pretransplant ESRD duration was over 180 days. In addition, in our Cox 
models, the duration of ESRD was analyzed as a continuous variable, and longer 
duration was associated with a better recipient survival.  We recognize that this outcome 
may potentially be explained by survivor bias, where only those patients with long 
duration of dialysis, who survived to transplant, were included in the study.  In the 
present study, the duration of dialysis was analyzed as both a continuous and a 
categorical variable, rather than simply as a binary variable describing preemptive 
versus nonpreemptive transplant. The 60-day rule (a convention adopted by USRDS, 
that a dialysis modality must continue for at least 60 days in order to be considered 
stable, and therefore dialysis duration for less than 60 days may not be reflected by the 
binary variable describing pretransplant dialysis) was not applied. Instead, the actual 
number of days for which the patient was dialyzed prior to transplant was analyzed.   
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There are many potentially confounding variables in renal transplant outcome 
studies, such as socioeconomic status, age, race, citizenship, and primary payer.  
Kasiske et al. demonstrated that some of these factors (race, ethnicity, education) are 
associated with receiving  a preemptive transplant [146].  In the study by Meier-Krische 
et al. [32], the authors have not adjusted for socioeconomic status and education level.  
In the study by Mange [148], authors have not adjusted for socioeconomic status or 
education. Instead, their model was adjusted for race and median household income for 
the ZIP code of recipient.  We adjusted our Cox models for recipient education level, 
primary source of payment, and citizenship as a surrogate for differences in the 
socioeconomic status. 
Finally, it is unclear from the existing literature if both HD and PD used prior to 
transplant affect the outcome of the transplant to the same extent.  We stratified the Cox 
models by predominant dialysis modality and demonstrated that the association between 
duration of dialysis and the graft and recipient survival for patients on HD and PD are 
essentially the same.  This study did not address other factors associated with dialysis 
prior to transplantation either in a negative (e.g., loss of job) or positive (e.g., potentially 
better compliance after exposure to dialysis) way. 
We confirmed that a longer duration of ESRD is associated with a worsening 
graft outcome; however, the association only becomes significant after 6 months of 
dialysis therapy, and after 3 years, no significant change in risk was evident.  Similarly, a 
longer duration of ESRD was also associated with a worsening recipient survival as well 
when calculated from the time of transplant. However, it only becomes significant after 1 
year of ESRD duration.   
This retrospective study did not address the mechanism of association described 
above. However, we speculate that clinically significant accumulation of ESRD related 
comorbidities and loss of residual kidney function occurs only after 6 months of exposure 
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to dialysis.  The negative effect of dialysis therapy and/or ESRD on the graft survival (but 
not recipient survival) plateaus at 1 year after initiation of dialysis.  This can potentially 
be explained by the fact that predictors of the graft survival (e.g., oxidative stress, loss of 
residual renal function, aberrant T-, B-cell, and cytokine production[153]) might be 
peaking at 1 year.  Additional factors affecting recipient survival (e.g., cardiovascular 
calcification) continue to accumulate after 1 year of dialysis therapy. 
Since dialysis for up to 6 months does not appear to adversely affect graft 
survival, these results suggest that patients who have uremic symptoms should not defer 
dialysis while waiting for kidney transplant [64]. 
 




The role of socioeconomic status of the donor and recipient in the graft and 
recipient survival remains controversial and poorly understood.  We and other authors 
previously demonstrated that donor and recipient race plays an important role in allograft 
survival [23, 154], and that long-term transplant outcomes in African American patients 
remain significantly lower than all other ethnic groups, independent of genetic matching 
[155].  However, it is not clear what impact genetic and environmental factors have on 
these racial disparities in allograft survival.  Furthermore, it has been demonstrated that 
racial differences affect the access to specific transplant procedures: in particular, 
kidney-pancreas transplant [156] are associated with different levels of compliance 
[157].  In addition, there are apparent disparities in chronic kidney disease care provided 
to ethnic minorities.  Disparities exist in wait-list time and kidney transplant rates for 
Native Americans and African American patients, independent of insurance status [155].  
African American patients were less likely than White patients to want a transplant and 
less likely to be referred for evaluation at a transplantation center and placed on a 
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waiting list.  These differences, however, explain only a small fraction of the substantial 
racial differences in access to transplantation [158].  While certain genetic factors 
associated with race might potentially play a role, literature reports suggest the presence 
of poorly understood social aspects contributing to the survival differences.  We 
hypothesized that certain socioeconomic factors, such as education level, 
citizenship/immigration status, and source of payment for medical service, play an 
important role in graft and recipient outcome.  The goal of this project was to evaluate 




4.7.2.1. Baseline characteristics 
The recipients (n=92,844) were 60% male, 70% Euro American, 23% African 
American, 3% Asian; and 27% diabetic, with an average age of 43 years at the time of 
the study transplant. Roughly one-in-eight (12.6%) had at least one prior transplant.  
These recipients were 59% male, 78% White, and 16% diabetic, with an average age of 
38.5 years at the time of the study transplant.   
 
4.7.2.2. Survival analysis 
While the models described here were not adjusted for the year of the 
transplantation due to a relatively short study period, we realize that the time of the 
transplant might still confound the results.  Therefore, additional analysis was performed 
after adjusting the model for the year of the transplant.  Also, since using the year of the 
transplant as an indicator of transplant era may introduce bias in the statistical analysis, 
we selected the use of mycophenolate mofetil, that came on the market in the mid-90s, 
as a surrogate for the transplant era.  Using both approaches revealed results very 
similar to our original analysis and are not presented here. 
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4.7.2.3. Role of education level 
Kaplan-Meier plots suggested incremental improvement in the outcome with 
increased education level. The proportional hazard model demonstrated improved 
outcome associated with more advanced education.  Compared with patients who 
receive grade to high school (0-12) education, those with some college to bachelor 
degree had significantly better graft (HR 0.93, p<0.005) and recipient (HR 0.90, p<0.005) 
survival.  Furthermore, recipients with postcollege graduate degrees had even better 
outcomes with HR 0.85 (p<0.005) for the graft and HR 0.88 (p=0.09) for recipient failure 
(Table 5).  When different racial groups were analyzed separately, African Americans  
and White patients (but not Asians) had a similar trend for graft survival.  Similar trends 
for recipient survival was observed only in White patients. 
 
4.7.2.4. Primary source of pay 
Based on Kaplan-Meier plots, recipients with private insurance had better 
outcomes than those with Medicare, Medicaid, or other sources of payment.  As far as 
recipient survival, patients on Medicare seem to have worse outcome than other groups, 
which could be confounded by older age.  In the entire patient population, using 
Medicare as a reference group, the proportional hazard model demonstrated statistically 
significant benefits to graft survival from having private insurance (HR 0.87, p<0.001).  
This effect was not observed in Asian recipients, but remained in African Americans (HR 
0.8, p<0.001) and Whites (HR 0.89, p<0.001).  Private insurance in comparison with 
Medicare also had an advantage for recipient survival in the entire group of patients (HR 
0.8, p<0.001) as well as in Asians (HR 0.66, p<0.05), African Americans (HR 0.71, 
p<0.001), and Whites (HR 0.83, p<0.001), when analyzed separately. Health 
maintenance Organizations (HMO) and Preferred Provider Organizations (PPO) were 
associated with a significantly higher risk of graft failure (HR 1.2, p<0.05) but  
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Table 5.  Proportional hazard model evaluating the role of socioeconomic status in graft 
and recipient survival1 
 
 Graft Survival Recipient Survival 
Variables HR (95%CI) p HR (95%CI) p 
Recipient education level 
Missing or Unknown 1.07 (1.03-1.12) <0.001 1.101 (1.04-1.17) <0.001
N/A: <5 yrs old 1.26 (0.98-1.62)   0.076 2.36 (1.5-3.72) <0.001
None 1.05 (0.83-1.31)   0.7 1.17 (0.87-1.59) 0.298
Grade to High School: 
grades 0-12 
reference 
Some College to 
Bachelor Degree 
0.93 (0.89-0.97) <0.005 0.9 (0.84-0.96) <0.005
Postcollege Graduate 
Degree 
0.85 (0.76-0.95) <0.005 0.88 (0.76-1.02) 0.09
Primary Source of Payment 
Medicare reference 
Missing or Unknown 1.00  (0.96-1.05) 0.865  1.12  (1.05-1.19) <0.001
Medicaid 1.00  (0.91-1.09) 0.916  0.92  (0.80-1.05) 0.214
US/State Government 
Agency 
1.00  (0.87-1.15) 0.957  0.84  (0.69-1.04) 0.108
Private Insurance 0.87  (0.83-0.90) <0.001 0.80  (0.76-0.85) <0.001
HMO/PPO 1.20  (1.02-1.42) <0.05 0.52  (0.36-0.74) <0.001
Other: Self, Donation, 
Free Care, VA, 
Pending, Foreign 
Government 
1.08  (0.85-1.38) 0.515  0.91  (0.63-1.32) 0.608
Recipient Citizenship   
U.S. Citizen reference 
Missing or Unknown 1.03  (0.97-1.10) 0.357 0.99  (0.91-1.08) 0.849
Resident alien 0.81  (0.74-0.88) <0.001 0.70  (0.62-0.80) <0.001
Nonresident alien 0.78  (0.54-1.13) 0.190 0.64  (0.35-1.15) 0.134
 
1 Only primary variables of interest are presented in the table.  The model was adjusted 
for the following covariates: recipient age, gender, race, BMI, history of DM, history of 
HTN, total duration of ESRD, cause of ESRD, mean and peak PRA levels, number of 
pretransplant transfusions, total number of transplants, number of different RRT 
modalities used, donor type, donor age, gender, race, BMI, heartbeating or not, donor 
history of DM, cold ischemia time, number of matched antigens. 
4.7.2.5. Role of citizenship. 
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improved patient survival (HR 0.52, p<0.001).  Having Medicaid, U.S./State Government 
agency, or other sources of payment for medical services did not show any significant 
association with outcome as compared with Medicare either in the whole patient 
population or in the subgroups divided by race. 
Kaplan-Meier plots suggested that resident and nonresident alien recipients had 
the best graft outcome and patient survival as compared to U.S. citizens.  Using the Cox 
model in the entire patient group with U.S. Citizens as the reference group, resident 
aliens had significantly better graft outcomes (HR 0.81, p<0.001).  When analysis was 
stratified by race, only in White patients did this association reach statistical significance 
(HR 0.823, p<0.001).  Similar results were observed for recipient survival, so where 
compared to U.S. citizens, legal aliens had a survival advantage (HR 0.7, p<0.001).  
This effect was observed in Asian patients (HR 0.66, p<0.05) and Whites (HR 0.7, 
p<0.001), but not in African Americans.  In addition, similar to resident aliens, 
nonresident aliens have better outcome than the U.S. citizens, but this finding did not 
reach statistical significance, likely due to the very small sample size of this group. 
 
4.7.2.5. Subgroup analysis: Adult patients with the first transplant 
We reanalyzed the subset of patients older than 18 when the first transplant 
occurred (n=78,181).  In this subset of the data, we found associations similar to those in 
the entire dataset.  Compared to patients with high school attendance, those with college 
education had a trend towards better graft (HR 0.96, p=0.0965, 95% CI 0.91-1.01) and 
recipient (HR 0.90, p<0.01, 95% CI 0.84-0.97) outcome.  Those with more advanced 
education had even better outcomes for the graft (HR 0.88, p<0.05, 95% CI 0.78-1.00) 
and recipient (HR 0.90, p=0.173, 95% CI 0.77-1.05) survival.  Compared to patients with 
Medicare (n=28,882), recipients who had private insurance (n=15,339) had a lower risk 
for the long-term graft failure (HR 0.86, p<0.001, 95% CI 0.82-0.90) and recipient death 
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(HR 0.80 p<0.001, 95% CI 0.76-0.85).  Having HMO/PPO (n=618) was associated with 
worse graft survival (HR 1.27, p<0.01, 95% CI 1.07-1.51) but better recipient survival 
(HR 0.54, p<0.005, 95% CI 0.37-0.78).  Also, resident aliens (n=1,739) had an 
advantage over the U.S. citizens for graft (HR 0.81 p<0.005, 95% CI 0.74-0.90) and 




Socioeconomic factors have been shown to affect health care outcomes.  
Poverty, unemployment, and low education levels have been listed among the factors 
adversely affecting health [159].  Socioeconomic status has been suggested to play a 
significant role in kidney transplant outcome.  Among others, the following 
socioeconomic factors have been listed as risk factors for posttransplant 
noncompliance: occupational status, educational level, language or cultural barriers, and 
ethnic background [160].  Race and income have substantial effects on mortality and 
use of services among Medicare beneficiaries [161].  Poor individuals are less likely than 
wealthy individuals to be medically suitable, to be interested in transplant, and to 
complete the pretransplant workup [162].   
In a study similar in design to our project and based on UNOS data, in patients 
with liver transplant, it has been shown that neighborhood income had no effect on graft 
or patient survival; education had only marginal influence on the outcome (survival was 
lower in those with a high school education than in those with graduate education); and 
patients with Medicaid and Medicare had lower survival when compared to those with 
private insurance [163].  The results of our study done in kidney transplant recipients are 
similar.  In the entire patient group, there is a statistically significant benefit to graft and 
patient survival from having private insurance compared to Medicare.  This effect was 
observed across almost all racial groups (except for Asians, where there was no 
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significant association between private insurance and graft survival).  HMO/PPO was 
associated with significantly higher risk of graft failure but improved patient survival.  
These results are similar to those reported in liver transplant recipients [163]. 
 Compliance with regards to immunosuppressive medication use is one of the key 
factors in prolonging graft survival.  Until 1993, Medicare regulations allowed for 
coverage of immunosuppressive medications for only 1 year posttransplantation unless 
the recipients maintain their Medicare beneficiary status through disability or age.  
Between 1993 and 1995, that duration was gradually extended to 3 years 
posttransplantation, which was further extended by 8 months in 2000. Woodward et al. 
[164] have shown that extending the coverage from 1 year to 3 years posttransplantation 
has eliminated the 4.5% difference in graft survival between low income and high 
income recipients.  In a follow-up analysis [165], the same authors estimated that if 
Medicare provided life-long immunosuppressive medications to all the recipients, graft 
failure would be reduced by 1.2% annually beginning in the fourth year 
posttransplantation.  Furthermore, Medicare beneficiaries who are eligible to receive the 
immunosuppressive medication coverage must still pay 20% of the cost of these 
medications, as Medicare covers only 80% of the total cost. With many HMO/PPO or 
private insurances, carrier subscribers may be required to pay substantially lower co-
payments.  This could also contribute to better compliance with immunosuppressive 
medications and subsequently, better graft outcome among HMO/PPO or private 
insurance subscribers compared with Medicare beneficiaries.  Medicare beneficiaries 
who underwent kidney transplantation do not have coverage for nonimmunosuppressive 
prescription drugs.  This could explain the poor recipient survival seen in our analysis. 
Medicare beneficiaries were shown to be more likely to take required prescription 
medications if they had prescription drug coverage [166].  Finally, even though we 
included age as an independent variable in our analysis, there may be a residual 
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confounding effect of age on the outcome.  As Medicare patients tend to be older 
compared to HMO/PPO or private insurance patients, Medicare beneficiaries may have 
poor outcome compared to non-Medicare recipients. 
 A possible reason for inferior outcomes in Medicaid beneficiaries is as follows:  
Previous studies have shown that Medicaid beneficiaries are less likely to receive 
optimal treatment, and their outcome is worse compared with privately insured patients 
for common conditions such as myocardial infarction and bronchial asthma [167, 168].  
Restricted access to medical care because of lower reimbursement by Medicaid and 
highly variable coverage benefits between different states are some of the possible 
explanations for such poor outcomes. Low income and poverty indicated by Medicaid 
may directly or indirectly contribute to worse health outcomes in general.  Indeed, cost-
related skipping of medications has been shown to be associated with the level of drug 
coverage and the income level [169].  A potential explanation for better outcomes among 
those with private insurance could be better quality of care.  Furthermore, these patients 
might be either healthy enough to be employed or have high enough personal incomes 
to be able to afford private insurance, both of which may potentially influence the 
outcomes.  
 Our study demonstrated that better recipient but worse graft survival is 
associated with HMO/PPO coverage.  Better graft survival does not always translate into 
improved recipient survival.  In this particular case, we hypothesize that the HMO 
population is likely to consist of relatively young employed patients.  The residual 
confounding effect of age might explain longer recipient survival as compared to 
Medicare beneficiaries.  Poor graft survival among HMO/PPO recipients is intriguing and 
difficult to explain.  Interestingly, in another study, no difference in clinical outcome was 
demonstrated between HMO and fee-for-service patients [170].  We speculate that 
higher co-pays and deductibles in these plans for specialist physician visits and 
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expensive immunosuppressive medications compared either to private insurance plans 
or Medicare/Medicaid may be a hindrance for the patients to comply with required 
posttransplant treatment.  Indeed, the HMO membership was associated with higher 
degrees of cost-related skipping of medications as compared to Medicare beneficiaries 
[169]. 
 Also, in our analysis, recipients with higher education level have better graft and 
patient survival.  There is a clear trend in incremental lowering of the hazard ratio for 
both graft failure and recipient survival with advanced education level.  Theoretically, 
people with higher level of education are more likely to be well-informed and have better 
awareness of posttransplant care, which could potentially improve outcomes.  The 
correlation between the better education status and compliance is arguable.  We also 
contemplated the possibility of the association between education level and insurance 
status, so that the effect of these variables on the outcome is not independent.  It seems 
logical that the insurance status would be associated with education level of the 
recipients.  To address this question, we evaluated the potential association between 
these variables in a bivariate (Chi-square) analysis.  We found a significant association 
between education level and insurance status (p<0.001).  In general, people with higher 
level of education tend to earn higher income.  For example, according to the US 
Census Bureau data [171], annual average earnings of workers with a bachelor’s degree 
was $45,678 in 1999 compared with $24,572 for those with only a high school diploma. 
Higher income may translate into better medical care, greater ability to pay for 
medication, which in turn may translate in to better graft and recipient survival.  This 
effect of the higher education on the outcome might or might not be independent of the 
insurance status.  To address this potential confounding effect of the education level on 
the insurance status, we constructed two separate models with each one having either 
the level of education or the type of insurance coverage and found that the results were 
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very similar to the main analysis that included both the variables.  This similarity 
suggests an independent association between the outcomes and the level of education 
and the type of insurance coverage. 
Finally, in our analysis, resident aliens seem to have a significantly better 
outcome than U.S. citizens in terms of both graft and recipient survival.  This effect was 
observed in Whites, but not in African Americans, and may be explained by a number of 
factors.  These results are somewhat counterintuitive, as previously, the negative 
association between foreign immigration status and the health outcome has been 
suggested [159].  Low income, unemployment, low level of education, lack of health 
insurance and access to quality health care along with anti-immigrant sentiment and 
discrimination in health care [159], as well as language barrier [172] have been listed as 
potential reasons.  However, due to the selection process, the transplant population 
might not reflect the general trends described in the immigrants.  Also, it is conceivable 
that people who recently arrived to the US might have certain differences in 
environmental factors compared to the people born in the US.  In a recent study, women 
from Poland and more recent migrants had generally more nutritious intakes, compared 
to US-born women, or earlier migrants [173].  In the year 2000, persons born outside the 
United States comprised an estimated 11.1% of the U.S. population [174].  In the report 
published by the Centers for Disease Control, women born outside the United States 
had better birth outcomes than their racial/ethnic US-born counterparts [175].  In 
addition, we speculate that the fraction of the foreign population immigrating to the US 
might not be simply a random slice of the foreign society, but rather the motivated and 
active part of it.  Therefore, one can hypothesize that there is a degree of selection bias 
when the outcome of the American citizens is compared to the foreign nationals living in 
the US.  The attitude towards medical care (e.g., commodity rather than active involved 
process), such as the physician authority and subsequent compliance with 
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recommendations might be different between Americans and foreigners.  While most of 
these potential reasons are merely speculative, some cultural differences in regard to 
specific aspects of medical care between Americans and foreign nationals have indeed 
been described in the literature [176].  
In general, based on our results, it seems that some of the socioeconomic factors 
are significant predictors of the outcome across racial groups.  This supports the 
independent role of these factors from the racial characteristics.  Also, in the studies 
analyzing the role of race in the transplant outcome, potentially uneven distributions of 
the socioeconomic factors in the different racial groups may confound the results of the 
analysis and hypothetically explain some of the differences in the outcome between the 
races.   
This study is a retrospective analysis utilizing data reported to the United States 
Renal Data System.  There are limitations as well advantages to large renal transplant 
database analyses.  Database analyses can show long-term differences in outcomes, 
and provide the statistical power to help determine the differences between the primary 
variables of interest.  However, the quality of data is always a concern due to a 
significant amount of missing and potentially erroneous information (misclassification 
bias).  In particular, socioeconomic status is difficult to quantify and subjects might be 
unwilling to share certain information (e.g., immigration status, education level).  For 
example, in our dataset, the education level variable is missing in 61% of the data. 
Therefore, the analysis of the role of the education status is based on the remaining 39% 
percent of the data (over 32,000 subjects).  It would be optimal not to have any missing 
values, but due to very large sample size of the remaining observations, the results are 
still valid.  One can assume a random pattern of missing elements in the data and 
analyze only records with nonmissing information.  While the random distribution of the 
missing values is likely, we decided not to discard the records with values missing, but 
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rather code and analyze them separately, as reported above.  Misclassification bias is 
difficult to address in the retrospective study and remains one of the shortcomings of the 
data registry analyses.   
Other potential problems with retrospective data analysis should be considered.  
As in other retrospective studies, while establishing the association between 
independent variables and the outcome, this analysis cannot ascertain causative 
relationships.  In addition, as in most retrospective studies, the results could be distorted 
by reverse causality described elsewhere [177].  Finally, as our multivariate models 
depend on the variables available in the dataset, certain potential confounders may not 
be included in the analysis (e.g., annual income, employment status, geographic 
location, IQ level, marital status).  Analysis of the role of these variables may present a 
new and exciting opportunity for future research. 
In conclusion, recipients with higher education level, resident aliens (as 
compared to US citizens), and patients with private insurance have an advantage over 
graft and recipient outcomes independent of racial differences [95]. 
 




In the last decade, the immunosuppressive armamentarium has increased 
substantially, and several choices are now available for immunosuppression in kidney 
transplant recipients.   Improvement in patient and graft survival over time has correlated 
best with the introduction of new more effective immunosuppressive agents.  These 
newer immunosuppressant medications have shown equal or superior short-term (1 
year) outcomes in comparison with the established immunosuppressive medications 
[178-180].  We have seen improvement in short-term graft survival, due in part to the 
reduction in the incidence of acute rejection episodes or potentially a better use of 
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existing medications [181].  Unfortunately, these improvements in immunosuppression 
and reduced incidence of acute rejection episodes have had only minimal effects on 
chronic allograft nephropathy and late graft loss [147, 182].  
There is a continuing shift in the calcineurin inhibitor used from cyclosporine to 
tacrolimus and in antimetabolites from azathioprine to mycophenolate mofetil.  Both 
tacrolimus and mycophenolate mofetil were introduced for kidney transplantation in  the 
mid-90s. Since then (in 2003), according to the Scientific Registry of Transplant 
Recipients, 67% of kidney transplant recipients received tacrolimus and 81% of kidney 
received mycophenolate mofetil at the time of discharge [183].   
There have been numerous clinical trials comparing the different 
immunosuppressive agents.  These trials have historically evaluated the short 1 year 
outcomes of graft and patient survival and have contained a relatively small number of 
patients.  The results from clinical trials utilizing tacrolimus and /or mycophenolate have 
varied in their outcomes.  
Clinical trials have shown superior graft survival with tacrolimus when compared 
to cyclosporine [184], while others have failed to show any significant differences in 
either graft or patient survival [178, 185].  Other trials have shown improved renal 
function for tacrolimus-based regimens when compared to cyclosporine-containing 
regimens but showed no significant differences in graft or patient survival [186].  On the 
other hand, in the brief report based on the UNOS Scientific Renal Transplant Registry 
analysis by Bunnapradist and Takemoto, the authors demonstrated better 3-year graft 
outcome in patients on cyclosporine + mycophenolate mofetil than in those on tacrolimus 
+ mycophenolate mofetil regimen [187].  Similar data for clinical trials comparing 
mycophenolate mofetil to azathioprine can be found.  Although mycophenolate mofetil 
has been shown to decrease the incidence of acute rejections when compared to 
azathioprine in renal transplant recipients, the 3-year follow-up of the United States and 
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the Tricontinental studies did not show an increase in graft survival [3, 188].  Ojo et al. 
have subsequently shown an improved 4-year graft survival in patients treated with 
mycophenolate mofetil when compared to azathioprine treated patients [189].  To date, 
long-term outcome studies of different immunosuppressive regimens are lacking.  The 
goal of this project was to analyze retrospective data provided by the United States 
Renal Data System and compare the graft and recipient outcome of kidney transplants 
managed with the three most common maintenance immunosuppressive protocols over 
the last 5 years of last century. 
In this project, the primary variable of interest was the type of maintenance 
immunosuppressive regimen at the time of discharge from the hospital.  Three regimens 
that were considered the most common maintenance protocols in the 1990s were 
selected for this analysis: prednisone + cyclosporine + mycophenolate mofetil (PCM); 
prednisone + tacrolimus + mycophenolate mofetil (PTM); and prednisone + cyclosporine 




4.8.2.1. Baseline characteristics 
Among recipients (n=31,012), average age was 44.2±14.3 years, 39.6% were 
females, 68.7% were White, and 23.3% were African Americans.  Patients on 
maintenance PCM were 55.2% (n=17,108), PTM 23.3% (n=7,225), and PCA 21.5% 
(n=6,679).  Since different immunosuppressive drugs were introduced at different time 
periods, we evaluated the prevalence of different immunosuppressive protocols in 
transplants performed in two different time periods during the study: prior to 1997 and 
during 1997 and later.  Prior to 1997, 38.1% of the transplant recipient were placed on 
PCA maintenance at the time of discharge, 50.1% were placed on PCM, and 11.9% on 
PTM protocols.  During and after 1997, 16.3% were placed on PCA maintenance, 56.8% 
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were palced on PCM, and 26.9% on PTM protocols.  We compared baseline 
characteristics of the patients in the three study groups using ANOVA for continuous 
variables and Chi-squared for the categorical variables.   
 
4.8.2.2. Survival analysis 
Using the PCM group as a reference, the Cox model demonstrated the increased 
risk for allograft failure associated with PTM (HR 1.08 p<0.05) and PCA (HR 1.14 
p<0.001) regimens (Table 6).  PCA (HR 1.15 p<0.005) but not PTM (HR 0.99 p=0.9) 
regimen was associated with increased recipient mortality.  This association is illustrated 
by Kaplan-Meier survival curves for donor and recipient survival. 
 
4.8.2.3. Transplant era 
Since clinical practice has evolved over the follow-up period of our study, we 
analyzed the outcomes of the transplants performed during two time periods as 
described above: (1) from January 1, 1995 and through December 31, 1996 (early 
period) and (2) from January 1, 1997 and through December 31, 1999 (late period).  
Among patients transplanted in the early period, 11.7% (7,448) were on PTM, 38.1% on 
PCA, and 50.2% on PCM.  Among those transplanted in the late time period, 26.9 % 
(n=23,564) were on PTM, 16.3% on PCA, and 56.8% on PCM.  Among the transplants 
performed in the early time period, using PCM as a reference group, PTM was 
associated with the significantly greater risk for graft failure (HR 1.16, p<0.05 95% CI 
1.01 - 1.33).  PCA was associated with nonsignificantly increased risk of graft failure (HR 
1.06, p=0.244, 95% CI 0.96 - 1.17).  Among the late time period, both PTM and PCA 
regimens were associated with significantly greater risk of graft failure (HR 1.10, p<0.05, 
95% CI 1.01 - 1.19 and HR 1.14, p<0.01, 95% CI 1.04 - 1.25, respectively).  Recipient 
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Table 6.  Cox model: graft and recipient survival in recipients on different 
immunosuppressive regimens 
 
 Graft survival Recipient survival 
 Hazard 
Ratio (95% CI) 
p Hazard 
Ratio (95% CI) 
p 
Recipient age (per year) 1.01 (1.01 - 1.01) <0.001 1.04 (1.03 - 1.04) <0.001 
Recipient gender female 0.96 (0.90 - 1.02) 0.169 0.93 (0.84 - 1.03) 0.140 
Recipient race 
   White 
 
reference 
   African American 1.25 (1.16 - 1.33) <.0001 1.04 (0.94 - 1.15) 0.429 
   Asian 0.72 (0.61 - 0.86) <0.001 0.66 (0.51 - 0.84) <0.005 
   Other 0.98 (0.85 - 1.13) 0.781 1.15 (0.94 - 1.39) 0.175 
Recipient history of 
diabetes 
0.96 (0.82 - 1.13) 0.626 1.14 (0.94 - 1.39) 0.197 
Recipient history of 
hypertension 
0.86 (0.78 - 0.95) <0.005 0.71 (0.63 - 0.81) <0.001 
Recipient height (cm) 1.00 ()0.99 - 1.00 <0.01 1.00 (0.99 - 1.00) 0.06 
Recipient weight (kg) 1.00 (1.00 - 1.01) <0.005 1.00 (1.00 - 1.00) 0.63 
Recipient comorbidity 
score 
1.07 (1.00 - 1.15) <0.05 1.29 (1.19 - 1.40) <0.001 
Total duration of 
pretransplant end-stage 
renal disease (per year) 
1.00 (0.99 - 1.01) 0.474 1.04 (1.03 - 1.06) <0.001 
Total number of 
transplants 
1.40 (1.30 - 1.52) <0.001 0.93 (0.81 - 1.07) 0.322 
Cause of ESRD 
   diabetes 
 
reference 
   hypertension 0.99 (0.85 - 1.15) 0.848 0.96 (0.79 - 1.16) 0.679 
   glomerulonephritis 0.89 (0.76 – 1.03) 0.122 0.79 (0.65 - 0.95) <0.05 
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Table 6 continued 
 
 Graft survival Recipient survival 
 Hazard 
Ratio (95% CI) 
p Hazard 
Ratio (95% CI) 
p 
Mean PRA level (%) 
 
1.00 (1.00 – 1.01) <0.05 1.00 (1.00 – 1.01) 0.13 
Peak PRA level (%) 
 
1.00 (1.00 – 1.00) 0.741 1.00 (1.00 – 1.00) 0.267 
Number of HLA 
matched antigens 
 






0.72 (0.65 – 0.80) <0.001 0.61 (0.53 – 0.71) <0.001 
Donor age (per year) 
 
1.01 (1.01 – 1.01) <0.001 1.01 (1.01 – 1.02) <0.001 
Donor gender female 
 
1.03 (0.97 – 1.09) 0.298 1.00 (0.92 – 1.09) 0.984 
Donor race 
   White 
 
Reference 
   African American 1.24 (1.14 – 1.34) <0.001 1.25 (1.11 – 1.41) <0.001 
   Other 1.20 (1.07 – 1.33) <0.005 0.96 (0.81 – 1.15) 0.676 
Donor height (cm) 1.00 (1.00 – 1.00) <0.001 1.00 (1.00 – 1.00) <0.05 
Donor weight (kg) 1.00 (1.00 – 1.00) <0.005 1.00 (0.99 – 1.00) <0.005 
Cold ischemia time 
   ≤6 hours 
 
Reference 
   >6 and ≤14 hours 0.83 (0.73 – 0.94) <0.005 0.86 (0.72 – 1.04) 0.117 
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Table 6 continued 
 
 Graft survival Recipient survival 
 Hazard 
Ratio (95% CI) 
p Hazard 
Ratio (95% CI) 
p 
   >19 and ≤24 hours 0.99 (0.88 - 1.12) 0.906 1.01 (0.84 - 1.21) 0.920 
   >24 and ≤30 hours 0.94 (0.83 - 1.07) 0.354 0.98 (0.81 - 1.18) 0.823 
Number of pretransplant 
transfusions: 




   1-5 1.08 (1.02 - 1.15) <0.05 1.29 (1.18 - 1.41) <0.001 
   6-10 1.07 (0.94 - 1.22) 0.328 1.31 (1.10 - 1.57) <0.005 
   >10 1.28 (1.11 - 1.47) <0.005 1.59 (1.31 - 1.94) <0.001 
Percent of ESRD time 
on HD 
1.00 (1.00 - 1.00) 0.069 1.00 (1.00 - 1.01) <0.05 
Percent of ESRD time 
on PD 




   Prednisone  + 





   Prednisone + 
Tacrolimus + MMF 
1.08 (1.01 - 1.15) <0.05 0.99 (0.90 - 1.10) 0.901 
    Prednisone + 
Cyclosporine + 
Azathioprine 
1.14 (1.07 - 1.22) <0.001 1.15 (1.04 - 1.26) <0.005 
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survival had no significant association either with PTM or PCA regimens in the early or 
late time periods.  For the early period, HR was 1.04 (p=0.693) and 1.10 (p=0.15) for the 
PTM and PCA regimens, respectively.  In the late time period, HR was 1.003 (p=0.96) 
and 1.14 (p=0.057) for the PTM and PCA regimens, respectively (Figure 10). 
 
4.8.2.4. Year of transplant 
To evaluate the outcome in patient cohorts with the same or similar duration of 
follow-up period, we stratified the analysis by the year of transplant, evaluating the 
patients who were transplanted in 1995 (n=997), 1996 (n=6,451), 1997 (n=8,160), 1998 
(n=8,379), and 1999 (n=7,025) separately.  Patients transplanted in 1995 would have 
had 5 to 6 years follow-up during the study; those transplanted in 1996 - 4 to 5 years of 
follow-up; those transplanted in 1997 – 3 to 4 years follow-up; etc.  For the graft survival, 
using PCM as a reference group, the results were as follows: in the recipients 
transplanted in 1995, the PTM regimen was associated with an increased risk of graft 
failure (HR 1.49, p<0.05), while the PCA regimen did not have any significant 
association.  In the recipients transplanted in 1996, no significant associations between 
the graft survival and maintenance immunosuppressive regimen were found.  For the 
recipients transplanted in 1997 and 1998, only PCA was associated with shorter graft 
survival (HR 1.14 and 1.25, respectively, p<0.05).  Finally, recipients of the kidney 
transplant in 1999 had an increased risk of graft failure associated with PTM (HR 1.17, 
p<0.05), while PCA did not have any significant association with graft survival.  We did 
not find any significant association between the maintenance immunosuppressive 
regimen and the recipient survival in the cohorts of patients stratified by the transplant 
year.   
 




Figure 10.  Illustration of the results of Cox proportional hazard model evaluating the 
role of immunosuppressive regimen.  Hazard ratio of the graft failure and recipient death 
in the entire group of patients and in the subgroups based on the transplant period (early 
vs. late), and donor type (deceased vs. living).  Patients on the Prednisone + 
Cyclosporine + Mycophenolate Mofetil used as a comparison/reference group (HR 1.0), 
significant associations (p values <0.05) indicated by *. 
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4.8.2.5. Living vs. deceased donor 
A separate analysis was performed for the recipients of living and deceased 
donor transplants.  Among the recipients of living donor kidney (n=8,924), 19.6% were 
on PTM, 23.4% on PCA, and the remaining 57% were on PCM regimen.  Among the 
recipients of the deceased donor kidney (n=22,088), 24.8% were on PTM, 20.8% were 
on PCA, and the remaining 54.4% were on the PCM regimen. 
In the recipients of the deceased donor graft using PCM as a reference group, 
PTM had no significant association with the allograft outcome (HR 1.04 p=0.284), while 
the PCA regimen was associated with 18% increased risk (HR 1.18, p<0.001, 95% CI 
1.1-1.27).  In the recipient of the living donor kidney, PTM (HR 1.22, p<0.01, 95% CI 
1.06 – 1.41) but not PCA (HR 1.05, p=0.51) was associated with the higher risk of graft 
failure as compared to PCM.  Furthermore, since the analysis is somewhat suggestive of 
a potential superiority of PCA over PTM regimen in the recipient of living kidneys, we 
repeated the Cox analysis in living donors with PTM group as a reference.  That 
provides direct comparison between PCA and PTM regimens.  While, as expected, the 
PCM regimen had an advantage over the PTM (HR 0.820, p<0.01, 95% CI 0.71 - 0.95), 
the PCA regimen was not significantly different from the PTM.  Therefore, we concluded 
that the PCM, but not the PCA maintenance regimen, is superior to PTM regimen in 
living donors. 
In the recipients of the deceased donor kidneys, the recipient survival had no 
significant association with the PTM regimen, but was significantly associated with the 
PCA regimen (HR 1.17, p<0.001, 95% CI 1.05 – 1.29).  In the recipient of the living 
donor kidney, the recipient survival had no significant association with either one of the 
maintenance immunosuppressive regimens (Figure 10). 
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4.8.2.6. Adult vs. pediatric recipients 
Separate analysis was performed for the recipients younger than 18 years of age 
(pediatric) and those 18 years and older (adult).  In pediatric patients (n=1,227), 18.3% 
were on PTM, 35.0% on PCA, and the remaining 11.7% were on PCM maintenance 
immunosuppressive regimen.  In adult recipients (n=29,785), 23.5% were on PTM, 
21.0% were on PCA, and 55.5% were on PCM regimen.  Among pediatric patients, we 
did not find any significant association between the drug regimen and the graft or 
recipient outcome.  In adults, the results were similar to those in the entire study 
population: PTM was associated with increased risk of graft failure (HR 1.08, p<0.05), 
but not recipient survival, while PCA was associated with increased risk for both graft 
failure (HR 1.14, p<0.001) and recipient death (HR 1.14, p<0.01). 
 
4.7.2.7. Kidney-only vs. simultaneous kidney pancreas 
(SPK) transplant 
 
We performed separate analyses of the recipients of kidney-only and recipients 
of SPK.  The information about SPK was missing in 542 patients; therefore, 28,404 
patients with kidney-only and 2,066 patients with SPK were included in the analysis.  In 
patients with kidney-only transplant, 20.9% were on PTM, 22.5% on PCA, and the 
remaining 56.6% were on PCM regimen.  In SPK recipients, 55% were on PTM, 7.6% 
were on PCA, and 37.4% were on PCM.  In SPK recipients, we did not detect any 
significant association between the drug regimen and either graft or patient survival.  In 
the recipients of kidney-only transplants, results were similar to those in the entire 
patient population: in comparison to PCM regimen, PTM was associated with increased 
risk of graft failure (HR 1.10, p<0.01) but not recipient death, while PCA was associated 
with both increased risk of graft loss (HR 1.15, p<0.001) and recipient death (1.16, 
p<0.005). 
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4.8.2.8. Effect of the induction therapy 
Since the results of the survival analysis potentially could be confounded by the 
induction therapy, we collected the data describing induction regimen divided into the 
following groups: muromonab-CD3 (OKT3), antithymocyte globulin (ATG), interleukin-2 
receptor monoclonal antibodies (IL-2R mAb): daclizumab or basiliximab, and “Other or 
Missing.”  The latter category included patients with no induction, those in whom 
induction therapy information was missing, and those in whom regimens other than 
OKT3, ATG, or IL-2R mAb induction were used.  Of the total patient population, ATG 
was used for induction in 5,152 patients, OKT3 in 3,904 patients, and IL-2R mAb in 
3,337 patients. The remaining recipients (n=18,619) were either on other induction 
therapy, or information was missing.  We included the information regarding the 
induction therapy into the Cox model and reanalyzed the data.  The results were similar 
to those reported above.  Using the PCM group as a reference, graft survival in the 
recipients on PTM and PCA regimens was associated with increased risk of graft failure 
(HR 1.07 p<0.05 and HR 1.15 p<0.001, respectively).  For recipient survival, only PCA 




Multiple factors have been shown to affect the outcome of renal transplantation.  
These include demographic characteristics [190] such as race and ethnicity [154], 
pretransplant dialysis course [66], and the timing of the transplant [64].  Patient response 
to the transplantation procedure (e.g., delayed graft function, acute rejection, acute 
tubular necrosis) is strongly associated with the long-term prognosis [191].  The 
selection of the appropriate immunosuppressive regimen (including induction and 
maintenance) is without doubt one of the most important modifiable factors that might 
affect the short-term events, as well as long-term results of the transplantation.   
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Determining the optimal maintenance immunosuppressive regimen in kidney 
transplantation is an area of continued research.  The immunosuppressive regimen that 
provides the best long-term outcome has yet to be defined.  There are multiple factors to 
consider when choosing a maintenance immunosuppressive regimen, including the side 
effect profile, cost, potency, and effect on allograft function [192].  Due to the short term 
outcomes and the lack of power of trials for new immunosuppressants, there is little 
information about the long-term graft outcomes associated with the different 
maintenance immunosuppressant regimens [193]. 
The short-term outcome of the kidney transplant, mostly expressed as an 
incidence of acute rejection, has been shown to be better with tacrolimus than with 
cyclosporine in both pediatric [194] and adult [195, 196] kidney transplant patients as 
well as in heart transplant recipients [197].  In lung transplant recipients, the episodes of 
acute rejections were similar in patients receiving cyclosporine and those receiving 
tacrolimus in combination with steroids and mycophenolate mofetil [198].  The data 
regarding long-term outcome are controversial.  In the recipients of living donor kidney 
transplants, cyclosporine + mycophenolate mofetil had better long-term outcome in 
terms of all-cause graft failure and death-censored graft failure than tacrolimus + 
mycophenolate mofetil protocol [187].  However, other authors report better 3-year 
outcome with tacrolimus-based regimens as compared to cyclosporine-based regimens 
[199, 200] or no significant difference between the protocols [201, 202].  In a recent 
study based on 2-year follow-up comparing tacrolimus and cyclosporine-based 
regimens, the authors demonstrated no difference in the graft loss between the 
regimens; however, renal function was better in patients receiving tacrolimus [195].  
Using the annualized change in glomerular filtration rate as an outcome, the superiority 
of the tacrolimus plus mycophenolate mofetil regimen in preserving renal function has 
been demonstrated in a study by Gill et al. [193].  The latter study, however, was 
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criticized for potential biases, including the nonuniform measurements of renal function 
between immunosuppressive regimens and between transplant centers [203].  Despite 
the lack of long-term outcome data, the trend in recent years has been towards a shift 
from cyclosporine-based to tacrolimus-based and from azathioprine to mycophenolate 
mofetil regimens [204]. 
We attempted the analysis of the kidney transplants performed during the last 5 
years of the last century to compare the long-term outcomes of the patients receiving 
three most frequently used drug protocols.  Since the data are available, we considered 
extending the study period into the earlier years of the 1990s but decided against it.  Our 
study period covers the use of all three immunosuppressive regimens of interest, while 
comparing the early 90s (where azathioprine and cyclosporine were mostly used) to the 
latter years (where tacrolimus and mycophenolate mofetil started to dominate) would not 
be a fair comparison, since major changes in practice took place during the 1990s.  
Stratifying analysis by the transplant era, as well as analyzing patient cohorts 
transplanted in the same year, to some extent should eliminate the factor of time and 
related issue of evolving clinical practice confounding the outcome. 
 This study demonstrates that the use of PTM and PCA as maintenance 
immunosuppression between 1995 and 1999 was associated with increased risk of graft 
failure by 9% (p<0.05) and 15% (p<0.001), respectively, as compared to the PCM 
protocol.  Using the PCA regimen was associated with recipient survival worsening by 
15% (p<0.005) as compared to PCM.  Similar results were reported by other 
investigators analyzing long-term outcome on the large kidney transplant datasets [187], 
where, using data from the UNOS Scientific Renal Transplant Registry, authors 
demonstrated that the death-censored graft failure is 25% higher in the tacrolimus + 
mycophenolate mofetil group as compared to cyclosporine + mycophenolate mofetil.  
Woodward et al. at the recent American Transplant Congress presented results of the 
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analysis, where graft survival in patients on PCM regimen was superior to those on PTM 
regimen in living [205] and deceased [206] donor kidney transplant recipients.  In the 
analysis of the secondary outcomes, the results seemingly are pointing in another 
direction.  Serum creatinine concentration values were consistently lower in the PTM 
group, except for the 7-year follow-up time point (Figure 11).  Results of this analysis 
should be interpreted cautiously.  Serum creatinine has been used in numerous studies 
as a surrogate outcome, when the longer follow-up period needed to observe graft 
failure is not feasible.  In this project, however, we feel that we have long enough follow-
up to adequately observe the “hard” outcomes (i.e., graft failure and recipient death) to 
make a conclusion.  In a way, it is probably less important what a patient’s serum 
creatinine value is at a given point in time, as long as his or her graft is surviving longer.  
In addition, while interpreting these results, one must realize one very important potential 
flaw of this type of analysis.   
 Comparing serum creatinine values among the groups at a given time point may 
be misleading since only those patients who survived to that time point are included in 
this analysis.  Therefore, if the PTM group were to have a higher graft failure rate, 
creatinine might be artificially lower in the surviving patients as compared to the PCM 
group, where fewer patients failed the transplant, and therefore average creatinine 
values might be artificially higher (survivor bias).  For example, it is conceivable that if 
two cohorts of patients were compared, and in the first one that graft failure rate is 
greater than in the second one, the average creatinine might also be lower in the first 
cohort, since only the “healthiest” patients remain in the study.  In the second cohort, 
where the graft failure rate is slower, more patients with dysfunctional grafts, which have 
not failed yet, would remain in the study, and therefore, the average creatinine might be 
higher.  This would still mean the better outcome (lower rate of graft failure) in the 
second cohort despite higher average creatinine concentration.   




Figure 11.  Results of mean serum creatinine concentration in the study groups at 6 
months, 1 year, 3 years, 5 years, and 7 years posttransplant associated with different 
immunosuppressive regimens.  Differences between the groups are significant by 
ANOVA (p<0.001) for 6-month, 1-year, and 3-year, (p<0.01) for 5-year follow-up.  
Differences are not significant for 7-year follow-up. 
 
 Another interesting finding of this study is a significantly lower rate of 
posttransplant malignancies in the PTM compared to PCM and PCA groups.  This 
phenomenon, however, did not translate into improved patient survival in the PTM group 
as compared to PCM group.  Contrary to our results, in a recent meta-analysis, no 
difference has been demonstrated between tacrolimus-based and cyclosporine-based 
regimens [207].  It has been suggested by other authors that induction therapy might be 
equally or even more important than the maintenance immunosuppression in developing 
posttransplant malignancies [208].  Adjusting our model for the induction therapy 
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demonstrated results similar to those which we detected in the model not adjusted for 
induction, suggesting lower risk of posttransplant malignancies with the PTM regimen. 
This study is a retrospective analysis utilizing data reported to the United States 
Renal Data System.  There are limitations as well advantages to large renal transplant 
database analyses.  Database analyses can show long-term differences in outcomes, 
but the results must be evaluated with caution.  Using a database such as the USRDS 
provides the statistical power to help determine the differences between current 
maintenance immunosuppressive regimens.  However, because the database does not 
contain information about the dose or duration of therapy, caution must be taken when 
making conclusions from the data.  Certain limitations should be considered when 
interpreting the results of this study.  Selection bias is a common flaw of a retrospective 
analysis.  Based on our results, the outcome of the cyclosporine-based regimen is 
superior to that of the tacrolimus-based protocol.  We recognize that during the early use 
of tacrolimus, there was a tendency to use it mostly in the higher risk population (e.g., 
those with higher PRA levels, retransplants, and African Americans), and hence the 
selection bias.  Indeed, we compared subgroups of patients on three 
immunosuppressive regimens of interest and found that there is a very small, though 
statistically significant, difference in the baseline characteristics between the study 
groups (Table 2).  To reduce this potential bias, we adjusted the Cox model for the risk 
factors of premature graft failure (e.g., recipient race, PRA levels, number of previous 
blood transfusions, number of previous transplants, and comorbidity index).  Including 
these potential confounding factors in the multivariate model should considerably reduce 
the bias.  In addition, we tried to reduce the selection bias by stratifying  the analysis by 
the transplant era, as tacrolimus became more of a “mainstream” medication (as 
opposed to be used in high risk patients only) in the later 1990s.  Also, since living 
donors might have been considered at lower risk and thus affect the choice of 
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immunosuppression, we stratified the analysis by donor type.  Finally, we analyzed 
pediatric and adult recipients and kidney and SPK recipients separately.  The negative 
association between the PTM regimen and graft survival was observed in the entire 
patient population.  Importantly, the observed negative association between the PTM 
regimen and the graft outcome was observed not only in the early period, but in the late 
period as well, when the use of tacrolimus was supposedly not limited only to the high-
risk patient population.  The negative association between the PCA regimen and graft 
survival was observed in the entire patient population and only in late, but not in early 
transplant periods, and only in deceased, but not in living donor transplants.  The 
described associations were also revealed in adult recipients and kidney-only recipients 
(but not in to pediatric and SPK recipients).  Specifically, there is no superiority of PTM 
as compared to PCM in SPK recipients.  Subgroup analysis of the recipient survival did 
not demonstrate any association between PTM regimen and the recipient survival either 
in the whole patient population, or in any of the subgroups.  As kidney transplant 
recipients survival is relatively long, it is conceivable that longer follow-up period is 
needed to observe enough events to demonstrate a difference between the PTM and 
PCM regimens.  The negative association between the PCA regimen and recipient 
survival was demonstrated in the whole patient population, but in the subgroup analysis, 
only patients transplanted with a deceased donor kidney, adult recipients, and those 
receiving kidney-only (as opposed to SPK) transplant had increased risk of death on this 
regimen.   
Unfortunately, any study evaluating the long-term outcome has to deal with the 
fact that the practice evolves during the time of the study.  We partially addressed this 
issue by performing analysis separately for early and late transplant eras.  However,  
clinical practice, even during the late era of the study (late 1990s), is different compared 
to the current practice in the early 2000s.  In particular, the proportion of various 
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immunosuppressive regimens during the study is different from that in the modern days.  
We tried to address that by performing additional analysis comparing centers that use 
particular regimen (PCM, PCA, or PTM) exclusively or predominantly.  However, the 
amount of missing data related to the immunosuppressive regimen evaluated separately 
by the transplant center prevented us from performing this analysis.  We did, in fact, 
identify the centers leaning towards one regimen or another; however, in every case we 
encountered a high amount of missing information that made the classification of the 
                 Ѩ                              Ī  
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          e potentially misleading and thus are not presented here.  Our study 
was performed in a retrospective fashion and unfortunately does not provide the 
explanations for the mechanism of the observed associations.  Future studies are 
needed to confirm this association and establish the mechanism of it.  In general, the 
difference in graft survival between two regimens may be explained by the difference in 
nephrotoxicity, associated comorbidity, different side effect profile, or center effect.   Furthermore, some of the patients in the tudy had relat vely short follow-up due 
to censoring.  Our study period included all transplants done since 1995 with the 
duration of follow-up through the end of 2000.  Of all patients included in the study, 997 
were transplanted in 1995 and therefore had 5-6 years of follow-up; 6,451 were 
transplanted in 1996 and had 4-5 years of the follow-up; 8,160 were transplanted in 
1997 and had 3-4 years of the follow-up;  while patients transplanted in 1998 (n=8,379) 
and 1999 (n=7,025) had relatively short follow-up (1-3 years). 
 In summary, our data suggest that prednisone + cyclosporine + mycophenolate 
mofetil regimen is associated with lower risk of graft failure compared to prednisone + 
tacrolimus + mycophenolate mofetil, and lower risk of graft failure and recipient death 




5. REVISED MODEL OF KIDNEY ALLOGRAFT  





Several significant predictors of suboptimal transplant outcome were previously 
identified in adults [102, 109, 114, 209, 210] and children [38, 62, 211] based on data 
from the United Network of Organ Sharing (UNOS) and the North American Pediatric 
Renal Transplant Cooperative Study (NAPRTCS).  Donor and recipient age [212], 
preexisting donor hypertension and diabetes [213, 214], nonheartbeating donor [215], 
prolonged cold storage time [102], retransplantation [216], pretransplant renal 
replacement therapy modality [66], duration of pretransplant end-stage renal disease 
[64], body mass index of donor and recipient [109], and recipient marital status [71], 
along with other factors, play important roles in the outcome.  However, the probable 
interaction of these factors, plus their potential to act in various combinations, make it 
difficult to predict the outcome in individual patients without using mathematical tools.  
Mathematical models would accurately predict graft survival duration as well as identify 
patients at risk and locate potentially modifiable risk factors. We previously described 
mathematical models predicting 3-year deceased graft survival [23].  However, that 
report was limited only to deceased donor kidney recipients, and the mathematical  
model was designed only to predict 3-year allograft survival.  The attempt herein 
described is undertaken to develop a tree-based model predicting the probability of graft 
survival at posttransplant years 1, 3, 5, 7, and 10. 





As described above, we used the data collected by the United States Renal Data 
System (USRDS) and UNOS which described all kidney allograft recipients (both 
pediatric and adults) who underwent kidney or kidney-pancreas transplantation during 
the period of January 1, 1990, through December 31, 1999.  The follow-up period was 
extended through December 31, 2000.  Censored data used for multivariate analysis to 
identify factors that have an association with the outcome were excluded from the 
prediction analysis, as described below.  Separate datasets were generated for each of 
the five prediction models.  These datasets included only uncensored records which had 
specific information of graft survival at a given time period (i.e., 1, 3, 5, 7, and 10 
posttransplant years in the respective datasets).  For example, for the 1-year prediction 
model, only patients with a known 1-year outcome were selected, while those who were 
censored due to insufficient duration of follow-up or other reasons were excluded.  From 
each of the datasets, 2/3 of the data were randomly selected into the training dataset 
and the remaining 1/3 into the testing dataset. The training set was used for knowledge 
acquisition (to generate the model), while validation was performed using the records 




The outcome was the time between the most recent kidney transplant and the 
failure of the graft.  For the purpose of the prediction model, the outcome was converted 
into 1, 2, 3, 5, 7, and 10-year transplant recipients and graft survivals as a binary 
variable. The graft failure definition did not include patient death with a functioning graft 
(i.e., death censored graft survival).  In the event that the information regarding death 
with a functioning graft was missing in the dataset, and the patient death date has been 
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found to be equal to the graft failure date, we assumed that the patient died with a 
functioning graft unless the cause of death specified in the UNOS file was coded (ICD-9) 
as one of the following: 3200, graft failure: primary failure; 3201 graft failure: rejection; 
3202 graft failure: technical; 3299 graft failure; other;  or 3903 miscellaneous: renal 
failure.   
 
5.2.3. Independent variables 
 
The following independent variables were considered and evaluated for inclusion 
in the prediction models. 
 
5.2.3.1. Recipient demographic and anthropometric data 
Recipient demographic and anthropometric data: age, race, gender, height, and 
weight.  Information was obtained from USRDS files SAF.PATIENT and SAF.TXUNOS. 
 
5.2.3.2. Variables describing recipient ESRD course 
Variables describing recipient ESRD course were obtained from SAF.PATIENT 
and SAF.RXHIST60 files: age of  onset of ESRD; total duration of pretransplant ESRD 
period (time between the first ESRD service and most recent transplant date); renal 
replacement therapy (RRT) modality immediately prior to current transplant; 
predominant RRT modality during ESRD course (defined as modality used for >50% of 
the ESRD period as previously described [66]); number of different RRT modalities 
used; the specific combination of RRT modalities; absolute time and percent time of the 
whole ESRD period that the patient was treated with specific RRT modality; history of 
transplants prior to the current one (yes/no); and total number of transplants (including 
the current one).  Since preemptive transplantation was reported to be advantageous in 
terms of graft survival [146, 148, 217], the binary variable defining preemptive transplant 
was considered for inclusion in the models. The definition of preemptive transplantation 
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was based on the variable PRTXDIAL from the SAF.TXUNOS file, as was done by other 
researchers [146].  In addition, since the PRTXDIAL variable was not collected prior to 
1995, we defined preemptive transplant from the SAF.RXHIST60 file, based on duration 
of ESRD and use of dialysis prior to the transplant of interest, as described before [64].  
The recipient’s dialysis network was used as a proxy for geographic location. 
 
5.2.3.3. Recipient comorbidity status 
Recipient comorbidity status was described by a composite comorbidity index 
similar to the one proposed by Davies, which has been shown to be strongly associated 
with the outcome in ESRD patients [113].  Other comorbidity indices have been 
proposed in literature, and since it has been demonstrated that Khan, Davies, and 
Charlson scores are appropriate for expressing the prognostic impact of comorbidity on 
mortality risk in patients with ESRD [218, 219], Davies’ approach was selected for its 
simplicity.  Also, the specific comorbid conditions used as separate variables were 
considered for the model: presence and duration of HTN and DM; history of coronary 
artery disease; symptomatic cerebrovascular disease; symptomatic peripheral vascular 
disease; history of malignant tumors; recipient medical conditions at listing; and 
functional status prior to transplant.  Information about coexisting conditions was 
obtained from the SAF.TXUNOS file, which was collected from the Transplant Candidate 
Registration Form prior to transplant (at the time of listing for the most recent transplant).  
 
5.2.3.4. Donor variables 
Donor variables: type of donor (deceased or living), age, race, gender, height, 
weight, and donor health conditions prior to donation (i.e., presence and duration of 
comorbidities: DM, HTN, CAD; smoking history; heart beating or not; donor 
cause/mechanism of death) were obtained from SAF.TXUNOS file. 
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5.2.3.5. Transplant procedure variables 
Transplant procedure variables were also obtained from SAF.TXUNOS file: cold 
ischemia time, transplant procedure type (e.g., single kidney, kidney-pancreas, double 
kidney transplant), transplant center where surgery was done, donor and recipient HLA 
match, maintenance immunosuppressive therapy at the time of discharge from the 
hospital (latter was obtained from  the SAF.TXIRUNOS file). 
 
5.2.4. Variables selection 
 
We used several strategies to select the optimal combination of predictors for the 
model.  The selection criteria were based on the predictive value of the variable 
weighted against the practicality of including it in the model.  Even though the longer list 
of the predictors may potentially improve the outcome of the model, using too many 
variables may compromise the parsimony and practical usefulness of the model in the 
clinical setting.  In particular, since the decision support tool might potentially be used in 
the pretransplant clinical environment, only variables available before transplantation 
were used in developing prediction algorithms.   
 
5.2.4.1. Survival analysis 
We performed the survival analysis using proportional hazards regression 
modeling for the purpose of identifying the set of statistically significant predictors of graft 
(p<0.05).  For the survival analysis, where outcomes were analyzed as time to event, 
allograft outcome was censored at the earliest of the following events: loss to follow-up, 
patient death, or study completion date (12/31/2000) and was analyzed as days to graft 
failure or censor.  For the purpose of variables selection, the survival analysis was 
supplemented by the logistic regression models, as described below. 
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5.2.4.2. Logistic regression modeling for variables selection 
We generated 5 separate logistic regression models predicting the graft survival 
as a binary variable at 1, 3, 5, 7, and 10 years of the follow-up.  We used a conservative 
approach to variable selection.  Only variables that had significant association (p<0.05) 
with the outcome in all of the 5 models were included in the final tree-based analysis. In 
other words, variables that were not significant in at least one model were excluded. 
 
5.2.4.3. Additional variables 
In addition to the variables selected by the algorithms described above, we also 
included several variables that were originally excluded.  These variables were 
considered to be important for the graft outcome prediction: recipient history of unstable 
angina, predominant renal replacement therapy modality in the pretransplant course and 
percent time on peritoneal dialysis [66], recipient history of hypertension, recipient 
gender, and donor gender.  
 
5.2.4.4. Additional selection 
Using the set of variables selected by these methods, we tested the tree-based 
model for convergence and demonstrated poor performance, which were thought to be 
due to potential collinearity in the data.  To make the model more practical and 
parsimonious, we evaluated the performance of the model with the shorter list of 
variables, excluding the variables that were considered nonessential.  The heartbeating 
donor variable was found to have significant missing information, while nonmissing data 
was collinear with donor type (living vs. deceased).  Variables describing cardiovascular 
disease history were collinear with the variable describing peripheral vascular disease 
history, and therefore, the latter was removed.  The variable describing the use of 
antihypertensive medications by the donor was largely homogenous and was also 
removed.  RRT modality immediately prior to transplant was not used, and instead 
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predominant RRT modality during ESRD course was included in the model.  We also 
excluded the variable describing dialysis network, since the model did not converge in its 
presence.  Based on R-squared statistics, the model based on the shorter list of 
variables (below) performed not worse than the one less parsimonious based on the 
longer list of predictors.   
 
5.2.4.5. Final list of predictors 
The final list included the following recipient variables: recipient race, gender, 
age, height, weight, recipient having a transplant prior to the current one (yes/no), total 
number of transplants (including the current one), the time recipient has been on the list 
prior to transplant, predominant renal replacement therapy modality, percent time on 
peritoneal dialysis prior to transplant, number of renal replacement therapy modalities 
used prior to transplant, specific combination of renal replacement therapy modalities, 
recipient comorbidity score, history of cardiovascular disease, history of unstable angina, 
history of diabetes, history of hypertension, presence of hepatitis B core antibodies, 
presence of hepatitis C antibodies, peak and most recent level of panel reactive 
antibodies, and primary source of pay for medical services. In addition, the following 
donor variables were used in the final model: donor race, gender, age, height, weight, 
donor type (living or deceased).  
Finally, we used the following transplant procedure variables: cold ischemia time, 
and number of matched HLA antigens, using MMF in the immunosuppressive regimen 
(as a proxy for the transplant era).  
 
5.2.5. Statistical analysis and prediction models 
 
Continuous variables were summarized using means and standard deviations.  A 
tree-based model analysis has been extensively described elsewhere [101] and was 
previously used by our group in the prediction of renal function of diabetics [220] and in 
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the prediction of kidney allograft survival [23].  Briefly, tree-based modeling, also called 
classification and regression trees, or CART, is a form of binary recursive partitioning 
which systematically separates data into two groups using regression of a single factor 
on the outcome.  Unlike traditional methods, tree-building techniques are ideally suited 
for the development of a reliable clinical decision rule, which can be used to classify new 
patients into categories according to predicted allograft outcomes, where traditional 
statistical methods are sometimes cumbersome to use, or of limited utility [101].  Tree-
based modeling works well when the regression variables are a mixture of categorical 
and continuous variables.  The algorithm is nonparametric, so no assumptions are made 
regarding the underlying distribution of values of the predictor variables.  Tree-based 
modeling requires relatively little input from the analyst, as the outcome is presented in a 
form of binary trees is easy to interpret by a nonstatistician. However, the model is 
limited in that the partitioning method leads to the predicted value being presented in a 
discrete format, which may not make full use of the information that continuous variables 
can provide [101]. 
 
5.2.5.1. Validation and performance testing 
To test the performance of the models, prediction algorithms were applied to the 
testing dataset, and the values of the predicted probability of graft failure were generated 
and compared to actual values of graft outcome.  
Two measures were used for the validation of the prediction models. The 
probability of graft failure predicted on a testing set was categorized into deciles, and for 
each category, the rate of graft failure was calculated and compared with the predicted 
value [23].  We also used receiver operating characteristic (ROC) curve analysis to 
evaluate and compare the performance of the models.  ROC (probability that for a 
randomly chosen pair of patients the predicted and observed graft survival are 
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concordant) analysis is a nonparametric method used to quantify the accuracy of the 
prediction.  It is a plot of the true positive rate against the false positive rate for the 
different possible cut-points of a prediction algorithm.  It shows the tradeoff between 
sensitivity and specificity (any increase in sensitivity will be accompanied by a decrease 
in specificity).  The closer the curve follows the left-hand border and then the top border 
of the ROC space (resulting in large area under ROC curve: an area of 1 represents a 
perfect prediction), the more accurate the model. The closer the curve comes to the 45-
degree diagonal of the ROC space (resulting in a smaller area under ROC curve: an 
area of 0.5 represents a worthless prediction), the less accurate the model.  The 
procedure ROCCOM in the software package STATA (Stata Corporation, College 




SAS (SAS Institute, Cary, NC) was used for descriptive statistics and survival 
analysis; S-Plus (Insightful, Seattle, WA) was used for logistic regression and tree-based 
modeling [23, 220]; and STATA (Stata Corporation, College Station, TX) was used for 




5.3.1. Descriptive statistics 
 
Data were collected from USRDS and included 92,844 records of patients 
receiving kidney or kidney-pancreas transplants starting January 1, 1990, and through 
December 31, 1999, with the follow-up period through December 31, 2000.  The study 
population characteristics are presented in Table 1.  The average age of patients was 
43.3 years, of which 60.3% were male, 70.2% were White, 27.2% were diabetics, 77.1% 
were on HD prior to transplant, and 12.6% had another kidney transplant prior to the 
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current transplant.  During the 11 years of the study, the graft failed in 34.9% of the 
patients.  Cold ischemia time was on average 15.5 hours.   
 
5.3.2. Prediction model generation 
 
5.3.2.1. Selection of training and testing datasets 
The same training and testing datasets were used for logistic regression and 
tree-based models.  The training and testing datasets were derived from the full dataset 
after records were shuffled in the random order (S-Plus code: menuRandomSample(data = 
knownoutcome1, replace = F, save.name = " knownoutcome1", show.p = T)).  As discussed above, roughly 
2/3 of the data were used for the training dataset (for example the S-Plus procedure to 
select the training data for 1-year outcome prediction: knownoutcome1.training <- 
remove.row(target = knownoutcome1, start.row = 60001, count = 32844)), while 1/3 was used for the 
model testing (knownoutcome1.testing <- remove.row(target = knownoutcome1, start.row = 1, count = 60000)).   
 
5.3.2.2. Comparison of the models with long and short list of  
Predictors 
 
As indicated above, we aimed at finding the most parsimonious model, and in 
this particular exercise compared the outcome of the model based on the short list of 
predictors with the model based on longer list of predictors.  We used R-squared to 
compare models (Rsquared.Model1.Short<-Rsquared(Model1.Short); Rsquared.Model1.Long<-
Rsquared (Model1.Long)) and found no differences in the outcome. 
 
5.3.2.3. Regression modeling 
The Regression Model was based on the list of predictors described above. Five 
different logistic regression models predicting the probability of the allograft survival for 
1, 3, 5, 7, and 10 years were generated using S-Plus software.  As an example, the code 
for the model predicted 1-year outcome is presented here: 
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Final.model1.reg <- menuBinomialGlm(formula = AA.GS~ UNSANGR.Cat + 
Predom.Mod + htnnew1 + tx.sex + DSEX + height + PKPRA + prev.tx + 
PRIPAY.Cat + tx.months + weight + tx.race + CVASCR + HBCORE + HCSRN 
+ DTYPE + DAGE + DRACE + Dheight + Dweight + match + MRPRA + 
C.COLDTIME + total.txs + RRage + time.onlist + MMF.Maint + RCITZ.Cat 
+ PTXTFUS.Cat + Comorb.Score + Mod.Number60 + Mod.Comb60 + pd.months 
+ hd.months + dmnew1, family = binomial, link = logit, variance = 
NULL, data = knownoutcome1.training, na.omit.p = T, trace = F, maxit 
= 50, epsilon = 0.0001, print.short.p = T, print.long.p = T, 
print.anova.p = F, print.correlation.p = F, save.fit.p = F, 
save.resid.working.p = F, save.resid.pearson.p = F, 
save.resid.deviance.p = F, save.resid.response.p = F, 
plotResidVsFit.p = F, plotSqrtAbsResid.p = F, plotResponseVsFit.p = 
F, plotQQ.p = F, smooths.p = T, rugplot.p = F, id.n = 3, 
plotPartialResid.p = F, plotPartialFit.p = F, rugplotPartialResid.p 
= F, scalePartialResid.p = T,  
newdata = knownoutcome1.testing, predobj.name = 
"knownoutcome1.testing", predict.type = "response", predict.p = T, 
se.p = T) 
pvalues1.final.reg <- anova(Final.model1.reg, test="Chi") 
menuCreateCategories(xname = "knownoutcome1.testing", col = "fit", 
numuse = "Cut Points", nbin = 10, numby = "Count", cutpoints = 
"0.1,0.2,0.3,0.4,0.5,0.6,0.7,0.8,0.9", newcol = 
"Predicted.Surv.Cutpoints") 
 
Variables used in the models are presented in Table 7.  Some variables had 
significant association with outcome in all or few of the five models.  This probably has to 
do with the fact that different factors are predicting the outcome at different 
posttransplant time points.  Few variables, however, were universally significant; in 
particular, higher degree of HLA match was associated with lower risk of graft failure, 
history of prior transplant increased the risk of graft failure in all but one models, while 
number of prior transplant was universally significant.  The living donor dramatically and 
significantly decreases the risk of graft failure in all models as compared to the deceased 
donor. A more detailed description of the direction and significance of the associations is 
presented in Table 7. 
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Table 7. Variables used in logistic regression models predicting the risk of graft failure, 
their regression coefficients and p-values. 
 
 1 year 3 years 5 years 7 years 10 years 
   p  p  p  p  p 
Recipient race: 
Asian 
1.0 0.97 0.8 <0.001 0.8 <0.001 0.7 <0.001 1.0 <0.001 
Recipient race: Black 1.4 <0.001 1.4 <0.001 1.6 <0.001 1.7 <0.001 1.7 <0.001 
Recipient race: 
White 
1.3 <0.001 0.9 0.08 0.9 0.18 0.9 0.25 0.9 <0.001 
Recipient sex: 
Female 
1.0 0.65 1.0 0.60 0.9 0.30 0.9 0.17 0.9 <0.001 
Recipient weight 1.0 <0.001 1.0 <0.001 1.0 <0.001 1.0 <0.001 1.0 <0.001 
How long on the list 
(years) 
1.0 <0.001 1.0 0.37 1.1 <0.001 1.1 0.01 2.4 <0.001 
Recipient height 1.0 <0.001 1.0 <0.001 1.0 <0.001 1.0 0.06 1.0 <0.001 
Number of HLA 
matched antigens 
0.9 <0.001 0.9 <0.001 0.9 <0.001 0.9 <0.001 0.9 <0.001 
History of prior 
transplant: Yes 
1.5 <0.001 1.5 <0.001 1.2 0.06 0.9 0.56 0.9 <0.001 
Total duration of 
ESRD (months) 
1.0 0.02 1.0 0.12 1.0 0.77 1.0 0.25 1.0 <0.001 
Total number of 
transplants 
1.5 <0.001 1.6 <0.001 1.6 <0.001 1.9 <0.001 2.1 <0.001 
Cause of ESRD: DM 1.1 0.52 1.2 0.05 1.5 <0.001 1.8 0.55 2.2 <0.001 
Cause of ESRD: GN 0.9 0.01 1.0 0.58 1.0 0.37 1.1 <0.001 1.1 <0.001 
Cause of ESRD: 
HTN 
1.1 0.23 1.0 0.34 1.1 0.02 1.2 0.40 1.6 <0.001 
Peak PRA level (%) 1.0 <0.001 1.0 0.02 1.0 0.14 1.0 0.05 1.0 <0.001 
Mean PRA level (%) 1.0 0.06 1.0 0.06 1.0 0.34 1.0 0.08 1.0 <0.001 








1.0 0.95 0.9 0.56 0.5 0.06 0.0 0.83 0.9 <0.001 
History of peripheral 
vascular disease: No 
0.9 0.84 1.2 0.42 1.0 0.38 1.0 0.85 1.1 <0.001 
History of peripheral 
vascular disease: 
Unknown 
0.9 0.75 1.0 0.29 1.0 0.96 0.1 0.06 1.2 <0.001 
History of unstable 
angina: No 
0.7 0.28 0.8 0.46 0.7 0.37 2.5 0.97 1.3 <0.001 
History of unstable 
angina: Stability 
unknown 
0.6 0.11 0.7 0.18 1.1 0.81 >9
99 
0.72 1.2 <0.001 
History of unstable 
angina: Stable 
angina 
0.8 0.14 0.8 0.09 0.9 0.57 3.2 0.39 1.2 <0.001 
History of unstable 
angina: Unknown 
0.6 0.07 0.6 0.06 0.6 0.19 3.1 0.96 1.2 <0.001 
Recipient history of 
HTN 
0.9 0.57 0.9 0.64 1.2 0.61 1.3 0.99 1.3 <0.001 
Recipient history of 
DM 
1.0 0.99 0.9 0.62 1.1 0.74 1.2 0.99 1.2 <0.001 
Donor age 1.0 <0.001 1.0 <0.001 1.0 <0.001 1.0 <0.001 1.0 <0.001 
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Table 7 continued 
 
 1 year 3 years 5 years 7 years 10 years 
   p  p  p  p  p 
Donor race: Black 1.4 <0.001 1.3 <0.001 1.3 <0.001 0.9 0.22 1.6 <0.001 
Donor race: White 1.1 0.36 1.1 0.47 1.0 0.56 0.7 <0.001 1.1 <0.001 
Donor sex: Female 1.0 0.38 1.0 0.45 1.0 0.06 0.9 <0.001 0.9 <0.001 
Donor type: Living 0.5 <0.001 0.5 <0.001 0.5 0.01 <0.
001 
0.58 1.3 <0.001 
Donor height 1.0 <0.001 1.0 0.42 1.0 <0.001 1.0 0.35 1.0 <0.001 








1.5 <0.001 1.0 0.91 0.2 <0.001 0.2 <0.001 1.1 <0.001 
Cold ischemia time 
<6 hours 
1.0 0.35 1.1 0.18 1.1 0.09 1.1 0.04 1.1 <0.001 
Cold ischemia 
time: >6 and <=14 
hours 
0.9 0.01 0.9 <0.001 0.9 <0.001 0.9 0.22 1.0 <0.001 
Cold ischemia 
time: >14 and 
<=19 hours 
0.9 <0.001 0.9 <0.001 0.9 0.07 0.9 0.24 1.1 <0.001 
Cold ischemia 
time: >19 and 
<=24 hours 
0.9 0.12 0.9 0.05 0.9 0.03 1.0 0.59 1.2 <0.001 
Cold ischemia 
time: >24 and 
<=30 hours 












1.2 0.06 1.0 0.73 0.7 <0.001 1.5 0.22 3.7 <0.001 
RRT modality prior 
to transplant: HD 
0.8 0.01 1.0 0.69 0.9 0.11 1.1 0.36 1.0 <0.001 
RRT modality prior 
to transplant: lost 
to f/u 
0.9 0.30 1.3 <0.001 1.0 0.77 1.2 0.28 0.9 <0.001 
RRT modality prior 
to transplant: PD 
0.9 0.20 1.1 0.38 0.9 0.16 1.2 0.32 1.0 <0.001 
RRT modality prior 
to transplant: TX 
3.2 <0.001 2.4 <0.001 1.8 <0.001 1.8 <0.001 1.0 <0.001 
Predominant RRT 
modality: HD 
1.0 0.76 1.2 0.30 1.2 0.16 1.1 0.74 1.4 <0.001 
Predominant RRT 
modality: None 
1.0 0.78 1.0 0.85 1.1 0.49 1.1 0.54 1.2 <0.001 
Predominant RRT 
modality: PD 
1.1 0.51 1.3 0.13 1.4 0.05 1.5 0.08 1.7 <0.001 
Number of months 
on HD 
1.0 <0.001 1.0 <0.001 1.0 0.06 1.0 0.03 1.0 <0.001 
Number of months 
on PD 
1.0 <0.001 1.0 0.02 1.0 0.02 1.0 0.08 1.0 <0.001 
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Table 7 continued 
 
 1 year 3 years 5 years 7 years 10 years 
   p  p  p  p  p 
Number of months 
with prior Tx 
1.0 0.56 1.0 0.87 1.0 0.19 1.0 0.32 1.0 <0.001 
Percent of ESRD 
time on HD 
1.0 0.93 1.0 0.17 1.0 0.92 1.0 0.84 1.0 <0.001 
Percent of ESRD 
time on PD 
1.0 0.27 1.0 0.02 1.0 0.24 1.0 0.02 1.0 <0.001 
Percent of ESRD 
time with prior 
transplants 
1.0 0.30 1.0 0.60 1.0 0.73 1.0 0.59 1.0 <0.001 
RRT modality: 
HD+Tx 
1.0 0.95 0.6 <0.001 0.6 <0.001 0.7 0.03 0.5 <0.001 
RRT modality: HD 
only 
1.3 0.19 1.0 0.66 1.0 0.86 1.0 0.49 1.1 <0.001 
RRT modality: 
None 
1.0 0.87 0.7 0.01 0.9 0.21 0.8 0.07 1.0 0.04 
RRT modality: 
PD+HD 
1.5 0.10 1.2 0.08 0.9 0.38 1.4 0.05 1.0 <0.001 
RRT modality: 
PD+HD+Tx 
1.0 0.94 0.6 <0.001 0.6 <0.001 0.8 0.32 0.5 <0.001 
RRT modality: 
PD+Tx 
1.3 0.22 0.8 0.15 0.8 0.26 1.1 0.67 0.8 <0.001 
RRT modality: PD 
only 
1.5 0.06 1.1 0.50 0.9 0.58 1.2 0.11 1.2 <0.001 
Number of different 
RRT modalities 
(>60 days) 
1.0 0.92 1.0 0.92 1.3 0.02 1.0 1.00 1.3 <0.001 
Donor Citizenship: 
US citizen 
1.0 0.69 1.0 0.51 1.0 0.71 0.8 0.05 0.7 <0.001 
Donor Citizenship: 
Missing 
1.2 0.14 2.1 <0.001 2.3 <0.001 1.1 0.69 0.7 <0.001 
Donor Citizenship: 
Nonresident alien 
0.9 0.62 1.0 1.00 0.8 0.46 0.4 0.10 1.0 0.10 
Donor Citizenship: 
Resident alien 
1.0 0.94 0.9 0.76 0.8 0.24 0.7 0.32 0.5 <0.001 
Donor Hx of DM 0-
5 years 
1.0 0.97 1.3 0.13 0.8 0.29 0.7 0.99 0.8 <0.001 
Donor Hx of DM 
>10 years 
1.0 0.96 1.1 0.71 1.2 0.59 0.5 0.98 0.8 <0.001 
Donor Hx of DM 6-
10 years 
0.8 0.54 0.9 0.62 1.6 0.25 0.5 0.98 1.2 0.01 
Donor Hx of DM: 
None 
0.9 0.23 1.0 0.88 0.8 0.36 0.2 0.90 1.1 <0.001 
Donor Hx of 
HTN:Missing 
1.4 0.14 1.9 <0.001 1.3 0.29 <<
0.0
011 
0.61 9.4 <0.001 
Heartbeating 
donor: missing 
0.7 0.08 0.5 <0.001 0.7 0.04 0.8 0.40 0.1 <0.001 
Heartbeating 
donor: No 





1.2 0.54 0.9 0.52 1.0 0.92 3.1 0.30 0.4 <0.001 
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Table 7 continued 
 
 1 year 3 years 5 years 7 years 10 years 
   p  p  p  p  p 
Recipient 
education level: 
Grade School (0-8) 
1.0 0.99 1.0 1.00 1.2 0.47 4.6 0.24 0.5 <0.001 
Recipient 
education level: 
High School (9-12) 























1.2 0.53 0.9 0.69 1.1 0.82 1.0 0.98 0.4 <0.001 
Hepatitis B core 
Ab: negative 
1.1 0.42 1.1 0.65 1.2 0.13 0.9 0.78 1.6 <0.001 
Hepatitis B core 
Ab: not done 
1.0 0.77 0.9 0.24 1.0 0.91 2.1 0.22 1.9 <0.001 
Hepatitis B core 
Ab: positive 
1.0 0.86 1.0 0.73 1.5 0.01 2.5 0.29 1.3 <0.001 





0.94 0.0 0.97 37.0 0.97 5.4 <0.001 
Hepatitis C: 
indeterminate 
1.3 0.75 1.2 0.82 0.3 0.28 0.0 0.81 0.1 <0.001 
Hepatitis C: 
negative 
1.1 0.43 1.2 0.08 0.9 0.40 3.0 0.06 1.6 <0.001 
Hepatitis C: not 
done 
1.1 0.41 1.1 0.60 0.9 0.31 0.7 0.58 0.8 <0.001 
Hepatitis C: 
positive 




















1.0 0.81 0.8 0.06 1.0 0.91 1.1 0.36 1.2 <0.001 
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Table 7 continued 
 
 1 year 3 years 5 years 7 years 10 years 













1.0 0.81 1.1 0.24 6.7 <0.001 1.0 1.00 1.1 <0.001 
Primary Source of 
Payment: Free 
Care 
0.6 0.50 0.1 <0.001 0.2 0.06 12.3 0.97 2.8 <0.001 
Primary Source of 
Payment: US/State 
Govt Agency 
0.5 0.14 0.3 0.01 0.5 0.33 1.0 1.00 3.3 <0.001 
Primary Source of 
Payment: 
HMO/PPO 
0.8 0.53 0.5 0.13 1.9 0.42 0.0 0.91 3.9 <0.001 
Primary Source of 
Payment: Medicaid 
0.5 0.09 0.3 0.02 0.7 0.65 0.0 0.89 2.9 <0.001 
Primary Source of 
Payment: Medicare 
0.5 0.12 0.3 0.01 0.6 0.43 0.0 0.89 2.0 <0.001 
Primary Source of 
Payment: Missing 
0.5 0.08 0.3 0.02 0.4 0.17 0.0 0.88 1.7 <0.001 
Primary Source of 
Payment: Private 
Insurance 
0.5 0.10 0.3 0.01 0.5 0.32 0.0 0.89 3.0 <0.001 
Primary Source of 
Payment: Self 
0.3 0.04 0.3 0.02 0.4 0.32 <<0.
001
1 





























1.0 0.92 0.8 0.50 1.4 0.44 0.8 0.70 0.3 <0.001 
Recipient age 1.0 <0.001 1.0 <0.001 1.0 <0.001 1.0 <0.001 1.0 <0.001 
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Table 7 continued 
 
 1 year 3 years 5 years 7 years 10 years 
   p  p  p  p  p 
Day of transplant: 
Friday 
1.1 0.01 1.0 0.33 1.0 0.24 1.0 0.94 0.9 <0.001 
Day of transplant: 
Monday 
1.1 0.21 1.0 0.90 1.0 0.43 1.0 0.70 0.9 <0.001 
Day of transplant: 
Saturday 
1.1 0.07 1.0 0.68 1.0 0.78 1.0 0.71 1.0 <0.001 
Day of transplant: 
Sunday 
1.0 0.91 1.0 0.97 1.0 0.35 1.0 0.84 0.9 <0.001 
Day of transplant: 
Thursday 
1.0 0.72 1.0 0.90 1.1 0.18 1.0 0.65 1.0 <0.001 
Day of transplant: 
Tuesday 
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5.3.2.4. Tree-based modeling 
Five different tree-based models predicting the probability of the allograft survival 
for 1, 3, 5, 7, and 10 years were generated.  TBM were initially generated without 
restrictions in order not to limit the list of independent variables described above.  To 
generate final, more parsimonious models, the optimal number of terminal nodes was 
determined for each model using the cross-validation procedure (S-Plus: 
plot(cv.tree(tree1))), where the deviance was plotted against the size of the tree to select 
the optimal tree size.  The optimal size of the tree was identified as 93 for the model 
predicting 1-year survival, 40 for 3-year survival, 88 for 5-year survival, and 65 for 7- 
year survival. The cross-validation procedure did not indicate the optimal tree-size for 
the 10-year outcome model; therefore, we arbitrarily selected the model with 65 terminal 
nodes (the same as for 7-year outcome prediction).  Following that, the second set of 
tree models was generated and pruned to the size identified by the cross-validation 
procedure.  After the models were created, the set of predicted outcome values was 
generated in the testing datasets.  The residual mean deviance of the model and 
misclassification error rate are presented in Table 2.   
As an example, the code for the tree-based model predicted 1-year outcome is 
presented here: 
finaltree1.response <- menuTree(formula = AA.GS~ DTYPE + Predom.Mod + htnnew1 + tx.sex + DSEX 
+ height + UNSANGR.Cat + PKPRA + prev.tx + PRIPAY.Cat + weight + tx.race + 
CVASCR + HBCORE + HCSRN + DAGE + DRACE + Dheight + Dweight + match + MRPRA + 
C.COLDTIME + total.txs + RRage + time.onlist + MMF.Maint + RCITZ.Cat + 
PTXTFUS.Cat + Comorb.Score + Mod.Number60 + Mod.Comb60 + dmnew1, data = 
knownoutcome1.training, print.summary.p = T, print.tree.p = T, , plot.it = F, plotUniform = T, plot.addText = T, 
plot.addText.what = "Response-Value", prune.p = T, prune.k = NULL, prune.best = 90, prune.method = "deviance", 
predict.newdata = knownoutcome1.testing, predict.type = "response", predict.save.name = "knownoutcome1.testing") 
menuCreateCategories(xname = "knownoutcome1.testing", col = "Yes", numuse = 




  123 
 
Variables that were used in tree-based model construction are presented in 
Table 8.  The table demonstrates the list of variables used for each of the five models in 
the order of their significance (from the root of the tree to the periphery.)  While different 
models used similar variables in the prediction of the outcome, they vary in the priorities 
assigned to the particular variables. 
 
5.3.3. Model validation 
 
5.3.3.1. Correlation analysis 
The predicted variable in this study is the probability of graft survival, which is a 
continuous variable.  However, the actual outcome for each individual patient is binary.  
All records were divided into 10 groups based on predicted probability of graft survival 
using the following cut-points: 0-10%, >10-20%, >20-30%, >30-40%, >40-50%, >50-
60%, >60-70%, >70-80%, >80-90%, and >90-100%.  The observed graft survival was 
calculated for each group and compared to the predicted probability using cross-
tabulation.   
Examples for cross-tabulation procedures for the logistic regressing and tree-
based model are presented here: 
Crosstab1 <- menuCrosstabs(formula = ~ Decile.LogRegr + AA.GS, data = 
knownoutcome1.testing, margin.p = T, na.action = "Fail", 
drop.unused.levels = T, print.object.p = T, digits = 2, marginal.totals 
= T, chi2.test = T)).   
 
Crosstab1 <- menuCrosstabs(formula = ~ Tree.Decile.Yes + AA.GS, data = 
knownoutcome1.testing, margin.p = T, na.action = "Fail", 
drop.unused.levels = T, print.object.p = T, digits = 2, marginal.totals 
= T, chi2.test = T) 
 
If the number of patients in a particular group was low (arbitrarily selected value 
of <30), it was merged with next group up, except for the very last group, and that was 
merged with the next group down.  In particular, for the 1-year prediction group, the 
models did not make any predictions with the probability of graft survival 0-10% and  
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11-20%; therefore, this group was merged with the group where the predicted probability 
of graft survival was 21-30%.  Similarly, the 31-40% group had only 7 patients and 
therefore was merged with the 41-50% group.  In the 3-year prediction model, none of 
the groups with predicted probability between 0 and 30% had any patients and therefore 
were merged with the 31-40% group.  In the 5-year model, the last group 91-100% had 
13 patients and was merged with the 81-90% group.  For the 7-year prediction, the 91-
100% group had only 21 patients and was merged with 81-90% group.  Finally, for the 
10-year prediction, none of the group greater than 60% had enough patients and were 
merged together in the 61-100% group. 
 The results of the analysis are presented in Table 9, where the percent of actual 
graft survival and number of patients for each of the groups of predicted probability of 
graft survival are presented.  These results are illustrated in Figure 12.   
The midpoint of each group’s probability range was used as the predicted 
percent survival for the group and compared to observed graft survival for the group by 
correlation analysis.  Similarly, the results of the validation in the testing dataset are 
presented in Figure 13 for the logistic regression model.   
For the tree-based model, the prediction of the probability of graft survival from 
the training model achieved a good correlation with the observed survival of the testing 
set with r= 0.94 for 1-year survival prediction; r= 0.98 for 3-year survival prediction; r= 
0.99 for 5-year survival prediction; r= 0.93 for 7-year survival prediction; and r= 0.98 for 
10-year survival prediction.  The results of the logistic regression model were very 
similar. 
 
5.3.3.2. Receiver operator characteristics (ROC) curve analysis 
The ROC analysis was performed for each model using the predictions 
generated on the testing dataset.  The ROC curves for the tree-based models are  









































































































































































































































































































































































































































































































































































































































Figure 12.  Bar plots of the graft survival rates vs. predicted probability of graft survival 
for one (Panel A), three (Panel B), five (Panel C), seven (Panel D), and ten (Panel E) 
years of graft survival.  Predictions were generated in the independent testing dataset, 
separate from the training dataset upon which the models were created. 














































Figure 12 continued 
 
 





































































Figure 13.  Bar plots of the graft survival rates vs. predicted probability of graft survival 
for one, three, five, seven, and ten years of graft survival for logistic regression model.  
Predictions were generated in the independent testing dataset, separate from the 
training dataset upon which the models were created.   
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Figure 13 continued 
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presented in Figure 14 (the results for the regression model were very similar).  The area 
under the ROC curve was calculated for each model using the prediction data generated 
on the testing dataset.  All models achieved a reasonable prediction accuracy on the 
independent testing dataset.  For 1-year prediction, the area under the ROC curve was 
0.63; for 3-year prediction: 0.64; for 5-year prediction: 0.71; for 7-year prediction: 0.82; 




Factors affecting kidney allograft survival were evaluated previously based on 
both local and national databases.  Other authors attempted to generate prediction 
models of the transplant outcome. A neural network model was used to predict the 
outcome of liver transplant [57, 221] and delayed graft function after renal 
transplantation [51].  Multivariate modeling was employed to predict living graft 
recipients’ creatinine based on four parameters: recipient age, BMI, creatinine clearance, 
and degree of relationship [222].   
As far as previous studies are concerned, we found one paper in which 
investigators used multivariate modeling to predict the outcome of the transplantation in 
order to optimize deceased kidney allocation decision making in a northern Italy 
transplant program [112].  However, to the best of our knowledge, aside from our report 
in 2003 [23], no other investigators have employed working prediction models to study  
long-term renal allograft outcomes.  
We previously presented mathematical models predicting the probability of 3-
year kidney allograft survival from a deceased donor based on UNOS data [23].  That 
model, however, had several limitations.  The model was based on the deceased donors 
only (as opposed to the current model based on both deceased and living donor kidney 
transplants), it employed a very limited set of predictors, and it was based on the  







Figure 14.  ROC curves for the prediction models of the one (Panel A), three (Panel B), 
five (Panel C), seven (Panel D), and ten (Panel E) years of graft survival.  ROC curves 
were generated in the independent testing dataset, separate from the training dataset 
upon which the models were created. 






Figure 14 continued 




Figure 14 continued 
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relatively old dataset.  In addition, the previously reported model predicted only 3-year 
allograft survival, while the currently reported model predicts the probability of 1, 3, 5, 7, 
and 10-year graft survival.  The previous analysis was also challenging in the face of a 
relatively large amount of missing data.  The current model is based on the more recent 
dataset, representing clinical practice modalities of the late 1990s.  In recent years, the 
quality of data has improved, especially since the introduction of UNet, the online 
transplant data entry system, that was implemented in October 1999.  In the current 
study, we used the data supplied by USRDS, which in addition to the UNOS data has 
information regarding patient dialysis course, more detailed patient comorbidity, and 
more comprehensive information on patients’ demographics.  In designing the study, our 
intent was to develop a prediction model to be used in the pretransplant setting; 
therefore, we excluded posttransplant variables that were not available until after the 
transplant procedure.  We also did not analyze the impact of immunosuppressive 
therapy, immediate posttransplant graft function, and episodes of acute rejection, since 
this information was not available prior to the transplantation procedure.   
The tree-based modeling used in this study represents a relatively new approach 
compared to conventional regression analysis of the data.  This nonparametric modeling 
works when the regression variables are a mixture of categorical and continuous 
variables in that it identifies "splitting" variables based on an exhaustive search of all 
possibilities, even in problems with many hundreds of possible predictors.  
Simultaneously, it requires relatively little input from the analyst.  This graphical 
algorithm, presented as a collection of simple binary rules, is much simpler to interpret 
by a nonstatistician than the multivariate logistic regression.  Prediction algorithms 
evaluated in this study can potentially be used in recipient counseling and decision- 
making processes regarding renal transplants. Tree-based modeling is easy to 
implement in the computer-based decision support system to be used in the 
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pretransplant clinic.  In addition, it can be used as a tool to identify patients at risk for 
premature graft failure, and to model different clinical situations, where the modifiable 
factors of the recipient, donor, and transplant procedures can be optimized.  The 
identification of factors that play an important role in graft survival helps to focus efforts 






 Predicting kidney transplant outcome based on the recipient and donor 
pretransplant characteristics is a first step towards personalized medicine in the 
management of transplant recipients.  Unfortunately, these efforts are difficult to 
undertake due to an insufficient amount of data in any given transplant center and the 
unclear role of some of the potential predictors.  In this project, we started with 
developing a pilot model of the long-term outcome prediction, and after validating the 
model and assessing its deficiencies, we have undertaken a series of projects to study 
the role of pretransplant dialysis course, socioeconomic status, immunosuppressive 
medications, and some other parameters in the graft and recipient survival.  This 
knowledge and the use of new, more complete set of data allowed us to generate a 
more sophisticated and more comprehensive yet practical prediction model, that can be 
used in the future development of the decision-support system. 
It should be mentioned that while different prediction models have specific 
advantages and disadvantages, it is difficult to predict which model would perform the 
best in a particular dataset.  Therefore, it is reasonable to use a multimodel approach to 
study which model is more appropriate for a given data structure. 
Certain limitations should be considered while interpreting the results of this 
project.  The dataset used covers the time period of the last 11 years of the last century.  
One should realize that there will always be a time gap, the data cannot be very recent, 
and a certain period of follow-up is necessary.  While this is the case, changes in clinical 
practice should be considered by the reader and potential users of the model.  
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Another limitation is the discrete type of the tree-based model output.  While the 
number of terminal nodes was relatively high, the output information is still limited due to 
the noncontinuous nature of the predicted probability.  Finally, as in every other analysis 
of the large registry data, the quality of the data is of concern.  That concern has been 
alleviated, however, by the recent improvement in the UNOS data collection techniques.  
Also, the relatively good performance of the models indirectly indicates the reasonable 
quality of the input data.   
This project was performed in the environment of biomedical informatics, which 
shaped the ultimate goal of the project to create the informatics tool potentially useful in 
clinical practice.  Specific approaches unique to the biomedical informatics field helped 
to develop the tools to accomplish this goal.  In particular, the initial part of the project 
involved manipulation of the large collection of medical data, including the combination 
of patient demographics, medical history, comorbidities, treatments, and outcomes.  The 
data was reformatted, cleaned, and internally validated.  Some of the variables 
underwent imputation of the missing values.  Knowledge discovery in the databases 
approaches were used for initial data analysis and prediction model design.  Several 
KDD approaches were explored in order to develop optimal prediction model and feature 
selection for the models.  While working on this project, the final goal of improving 
patient care was always in sight.  As results of the efforts presented here, we generated 
several mathematical models predicting the probability of the kidney allograft failure at 
different time points of the posttransplant period.  Prediction models represent either 
regression model or recursive partitioning algorithm that can be easily coded and be 
used as a core for the decision support system.  Other specific biomedical informatics 
approaches are presented in Table 10. 
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Table 10. Biomedical informatics aspects of this project 
Project stage Medical informatics aspect 
Acquire data from national data 
registry 
Data cleaning, validation, integration 
Medical data acquisition and manipulating 
large dataset, including data integration, 
storage, validation, formatting, imputation, 
and use 
Develop preliminary prediction model Creating the core of the decision support 
system 
Knowledge discovery in the databases 
Evaluate potential predictors of the 
outcome 
Public health and consumer use of health 
information 
Variable selection for the prediction 
modeling 
Machine learning techniques 
Develop refined prediction model Creating the core of the decision support 
system 
Personalized medicine 
Medical education using information  
technology 
Patient informatics 







In conclusion, we studied the role of several potential predictors in the transplant 
outcome and showed their association with kidney transplant outcome.  Furthermore, we 
developed and validated a prediction model of allograft survival in patients with kidney 
transplants.  The models predicting the probability of 1, 3, 5, 7, and 10-year allograft 
survival have been validated on the independent dataset and demonstrated performance 
that may suggest implementation in the clinical decision support system.  Evaluating 
these models, in a prospective study, may be the subject of a future project.   
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